View Filing Data

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Jul. 31, 2013	Sep. 06, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jul. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Trading Symbol	ADXS
Entity Common Stock, Shares Outstanding		5,024,081
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Current Fiscal Year End Date	--10-31
Entity Filer Category	Smaller Reporting Company

BALANCE SHEETS - USD ($)	Jul. 31, 2013	Oct. 31, 2012
ASSETS
Cash	$ 40	$ 232
Prepaid expenses	55,111	25,798
Other current assets	33,182	8,182
Deferred expenses - current	1,323,511	860,293
Total Current Assets	1,411,844	894,505
Deferred expenses - long term	289,834	342,007
Property and equipment (net of accumulated depreciation)	61,442	78,068
Intangible assets (net of accumulated amortization)	2,499,791	2,413,755
Deferred financing cost (net of accumulated amortization)	62,034	49,024
Other assets	38,438	38,438
TOTAL ASSETS	4,363,383	3,815,797
LIABILITIES AND SHAREHOLDERS' DEFICIENCY
Accounts payable	5,541,431	5,155,797
Accrued expenses	1,242,464	1,367,412
Short term convertible notes and fair value of embedded derivative	2,037,962	2,089,099
Notes payable - former officer	427,606	477,274
Notes payable - other	0	250,000
Total Current Liabilities	9,249,463	9,339,582
Deferred rent	0	4,803
Long-term convertible note	1,104,680	0
Common stock warrant liability	736,059	434,136
Total Liabilities	11,090,202	9,778,521
Commitments and Contingencies
Shareholders' Deficiency:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; issued and outstanding 740 at July 31, 2013 and at October 31, 2012. Liquidation preference of $10,277,570	0	0
Common stock - $0.001 par value; authorized 25,000,000 shares, issued and outstanding 4,898,248 at July 31, 2013 and 3,158,433 at October 31, 2012.	4,898	3,158
Additional paid-in capital	64,083,331	52,119,567
Promissory note receivable	(10,633,584)	(10,484,022)
Deficit accumulated during the development stage	(60,181,464)	(47,601,427)
Total Shareholders’ Deficiency	(6,726,819)	(5,962,724)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIENCY	$ 4,363,383	$ 3,815,797

BALANCE SHEETS [Parenthetical] - USD ($)	Jul. 31, 2013	Oct. 31, 2012
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	25,000,000	25,000,000
Common stock, shares issued	4,898,248	3,158,433
Common stock, shares outstanding	4,898,248	3,158,433
Series B Preferred Stock [Member]
Preferred stock, shares issued	740	740
Preferred stock, shares outstanding	740	740
Liquidation preference	$ 10,277,570	$ 10,277,570

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended		137 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013
Revenue	$ 0	$ 0	$ 0	$ 0	$ 1,863,343
Research & development expenses	1,319,936	1,331,415	4,411,793	5,760,158	34,214,629
General & administrative expenses	1,733,677	2,251,725	6,299,670	4,297,110	33,168,179
Total Operating Expenses	3,053,613	3,583,140	10,711,463	10,057,268	67,382,808
Loss from Operations	(3,053,613)	(3,583,140)	(10,711,463)	(10,057,268)	(65,519,465)
Other income (expense):
Interest expense	(142,842)	(1,045,297)	(600,004)	(4,241,805)	(15,585,869)
Other income (expense)	(17,372)	25,375	(15,926)	25,715	243,783
Gain (Loss) on note retirement	1,723	(932,421)	349,009	(2,173,491)	(643,933)
Net changes in fair value of derivative liabilities	1,616,919	2,430,914	(2,326,843)	6,020,434	18,715,454
Net Loss before benefit for income taxes	(1,595,185)	(3,104,569)	(13,305,227)	(10,426,415)	(62,790,030)
Income tax benefit	0	0	725,190	346,787	2,652,450
Net Loss	(1,595,185)	(3,104,569)	(12,580,037)	(10,079,628)	(60,137,580)
Dividends attributable to preferred shares	185,000	185,000	555,000	555,000	2,877,570
Net Loss applicable to common stock	$ (1,780,185)	$ (3,289,569)	$ (13,135,037)	$ (10,634,628)	$ (63,015,150)
Net Loss per share, basic and diluted (in dollars per share)	$ (0.37)	$ (1.19)	$ (3.13)	$ (4.45)
Weighted average number of shares outstanding, basic and diluted (in shares)	4,775,772	2,774,814	4,190,062	2,387,443

STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended		137 Months Ended
STATEMENTS OF CASH FLOWS - USD ($)	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013
OPERATING ACTIVITIES
Net loss	$ (12,580,037)	$ (10,079,628)	$ (60,137,580)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash charges to consultants and employees for options and stock	3,103,122	877,251	8,240,668
Amortization of deferred financing costs	28,909	0	342,556
Amortization of discount on convertible promissory notes	18,392	1,331,368	2,728,769
Impairment of intangible assets	0	0	26,087
Non-cash interest expense	528,023	2,885,053	11,889,712
(Gain) Loss on change in fair value of derivative liabilities	2,326,843	(6,020,434)	(18,715,454)
Warrant expense	30,887	0	795,247
Settlement expense	364,335	0	629,335
Employee Stock Purchase Plan	21,029	9,727	39,330
Value of penalty shares issued	0	0	149,276
Depreciation expense	13,626	9,184	223,074
Amortization expense of intangibles	117,920	109,859	860,562
Write off of intangible assets	0	0	33,211
Interest income	0	0	267
Loss (Gain) on note retirement	(349,009)	2,173,491	643,933
Changes in operating assets and liabilities :
Decrease (increase) in prepaid expenses	(42,243)	(2,452)	(68,040)
(Increase) in other current assets	(25,000)	(30,961)	(33,182)
(Increase) in other assets	0	0	(132,271)
(Increase) decrease in deferred expenses	(411,045)	365,925	(1,105,617)
Increase (decrease) in accounts payable and accrued expenses	1,914,577	4,445,333	14,418,838
(Decrease) in deferred rent	(4,803)	(43,228)	0
Increase in interest payable	24,840	24,759	17,542
Net cash used in operating activities	(4,919,634)	(3,944,753)	(39,153,737)
INVESTING ACTIVITIES
Cash paid on acquisition of Great Expectations	0	0	(44,940)
Proceeds from sale of equipment	3,000	0	3,000
Purchase of property and equipment	0	(91,844)	(241,937)
Cost of intangible assets	(203,955)	(258,940)	(3,424,600)
Net cash used in investing activities	(200,955)	(350,784)	(3,708,477)
FINANCING ACTIVITIES
Proceeds from convertible notes	2,110,500	500,000	19,969,900
Repayment of convertible notes	0	(87,941)	(1,649,030)
Payment of deferred offering expenses	(21,919)	(58,500)	(133,919)
Cash paid for deferred financing costs	0	0	(584,493)
Proceeds from notes payable	0	2,388,963	250,000
Proceeds from former officer loan	11,200	0	1,458,685
Repayment of former officer loan	(85,700)	0	(1,220,700)
Deferred investment funds	0	50,000	0
Net proceeds from issuance of Preferred Stock	0	0	8,610,499
Payment on cancellation of warrants	0	0	(600,000)
Proceeds from exercise of warrants	94,444	411,765	1,761,210
Net proceeds of issuance of common stock	3,011,872	0	15,000,102
Net cash provided by financing activities	5,120,397	3,204,287	42,862,254
Net increase (decrease) in cash	(192)	(1,091,250)	40
Cash at beginning of period	232	1,096,538	0
Cash at end of period	$ 40	$ 5,288	$ 40

Supplemental Disclosures of Cash Flow Information - USD ($)	9 Months Ended		137 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013
Cash paid for Interest	$ 188	$ 53,027	$ 788,205
Cash paid for Taxes	0	2,080	16,453
Supplemental Schedule of Non-cash Investing and Financing Activities
Equipment acquired under notes payable	0	0	45,580
Common stock issued to Founders	0	0	40
Notes payable and accrued interest converted to preferred stock	0	0	15,969
Stock dividend on preferred stock	0	0	43,884
Accounts payable from consultants settled with common stock	12,307	62,275	126,560
Notes payable and embedded derivative liabilities converted to common stock	1,962,599	4,636,255	10,604,969
Intangible assets acquired with notes payable	0	0	360,000
Intangible assets acquired with common stock	0	0	70,000
Debt discount in connection with recording the original value of the embedded derivative liability		306,568	6,473,385
Allocation of the original secured convertible debentures to warrants	0	0	214,950
Allocation of the warrants on convertible notes as debt discount		279,807	2,710,406
Cancellation of note receivable in connection with preferred stock redemption	0	0	(3,051,000)
Note receivable in connection with exercise of warrants	0	0	9,998,210
Common stock issued in exchange for warrants	0	134,796	134,796
Warrants Issued in connection with issuance of common stock	0	0	1,505,550
Warrants Issued in connection with issuance of preferred stock	$ 0	$ 0	$ 3,587,625

NATURE OF OPERATIONS AND BASIS OF PRESENTATION	9 Months Ended
NATURE OF OPERATIONS AND BASIS OF PRESENTATION	Jul. 31, 2013
Nature Of Operations and Basis Of Presentation [Abstract]
Nature Of Operations and Basis Of Presentation [Text Block]	1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION Advaxis Inc. (the “Company”) is a clinical development stage biotechnology company with the intent to develop safe and effective immunotherapies for cancer and infectious diseases. These immunotherapies are based on a platform technology under exclusive license from the University of Pennsylvania (“Penn”) that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm strains use a fragment of the protein listeriolysin (“LLO”), fused to a tumor associated antigen (“TAA”), or other antigen of interest. The Company refers to these as Lm -LLO immunotherapies. The Company believes these Lm- LLO agents redirect the potent immune response to Lm that is inherent in humans, to the TAA or antigen of interest. Lm -LLO based immunotherapies stimulate the immune system to induce antigen-specific anti-tumor immune responses involving both innate and adaptive arms of the immune system. In addition, this technology facilitates the immune response by altering the microenvironment of tumors to make them more susceptible to immune attack. The Company’s lead construct, ADXS-HPV, is being evaluated in four ongoing clinical trials for human papilloma virus (“HPV”)-associated diseases as follows: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (with the Gynecologic Oncology Group (“GOG”), largely underwritten by the National Cancer Institute (“NCI”);head and neck cancer (with the Cancer Research, United Kingdom (“CRUK”), (U.K) and anal cancer (Brown University, Oncology Group (“BrUOG”), U.S.). In addition, the Company has developed immunotherapies for prostate cancer and HER2 overexpressing cancers (such as breast, gastric and other cancers in humans and osteosarcoma in canines). Over fifteen distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence. Since inception in 2002, the Company has focused its development efforts on understanding its technology and establishing a drug development pipeline that incorporates this technology into therapeutic immunotherapies, currently those targeting HPV-associated diseases (cervical cancer, head and neck cancer and anal cancer), prostate cancer, and HER2 overexpressing cancers. Although no immunotherapies have been commercialized to date, research and development and investment continues to be placed behind the pipeline and the advancement of this technology. Pipeline development and the further exploration of the technology for advancement entail risk and expense. The Company anticipates that its ongoing operational costs will increase significantly as it continues conducting its clinical development program. Liquidity and Financial Condition The Company’s products are being developed and have not generated significant revenues. As a result, the Company has suffered recurring losses and its liabilities exceed its assets. These losses are expected to continue for an extended period of time. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. There is a working capital deficiency, a shareholders’ deficiency and recurring losses from operations that raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amount and classification of recorded assets and liabilities should the Company be unable to continue operations. Management’s plans are to continue to raise additional funds through the sales of debt or equity securities. Subsequent to July 31, 2013, the Company raised an aggregate of approximately $800,000 in additional capital through the sale of equity securities and convertible promissory notes. If the Company fails to raise a significant amount of capital, it may need to significantly curtail or cease operations in the near future. Any sale of common stock below $3.16 per share (as may be further adjusted) with respect to certain of its outstanding debt instruments or $15.11 per share (as may be further adjusted) with respect to certain of its outstanding warrants will trigger significant dilution due to the anti-dilution protection provisions contained therein. The Company recognizes it will need to raise additional capital over and above the amount raised subsequent to July 31, 2013 in order to execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables and reduce overhead until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. Accordingly, the accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily represent realizable or settlement values. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis of Presentation The accompanying unaudited interim financial statements include all adjustments (consisting only of those of a normal recurring nature) necessary for a fair statement of the results of the interim period. The October 31, 2012 balance sheet is derived from the audited balance sheet included in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2012 (the “Form 10-K”). These interim financial statements should be read in conjunction with the Company’s financial statements and notes for the fiscal year ended October 31, 2012 included in the Form 10-K. The Company believes these financial statements reflect all adjustments and reclassifications that are necessary for a fair presentation of its financial position and results of operations for the periods presented. Estimates The preparation of financial statements in accordance with U.S. Generally Accepted Accounting Principles (GAAP) involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ substantially from these estimates. Significant estimates include the fair value and recoverability of the carrying value of intangible assets (patents and licenses), the fair value of options, the fair value of embedded conversion features, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results may differ from estimates. Reverse Stock Split At the Annual Meeting of Stockholders held on June 14, 2013, the Company’s stockholders approved the filing of a Certificate of Amendment to effect a reverse stock split of its issued and outstanding common stock, and the filing of a Certificate of Amendment to decrease the total number of its authorized shares of common stock. On July 11, 2013, the Company’s Board of Directors authorized a reverse stock split at a ratio of 1-for-125 and approved the implementation of the authorized share capital decrease after the effectiveness of the reverse stock split. Accordingly, the Company amended its Amended and Restated Certificate of Incorporation by the filing of two Certificates of Amendment with the Delaware Secretary of State as follows:(a) on July 11, 2013, to effect a 1-for-125 reverse stock split of its outstanding common stock, par value $0.001 per share, to take effect on July 12, 2013 at 4:30 p.m. EDT, and (b) on July 12, 2013, to decrease the total number of authorized shares of common stock on a post-reverse stock split basis, so that the total number of shares that the Company has the authority to issue is 30,000,000 shares, of which 25,000,000 shares are common stock and 5,000,000 shares are ‘‘blank check’’ preferred stock. The reverse stock split was effective at approximately 4:30 p.m. EDT on July 12, 2013, and the share capital decrease took effect thereafter upon filing with the Delaware Secretary of State. All references in this Report to number of shares, price per share and weighted average number of shares of common stock outstanding prior to this reverse stock split have been adjusted to reflect the reverse stock split on a retroactive basis, unless otherwise noted.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Jul. 31, 2013

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

Revenue from license fees and grants is recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) services have been rendered, (iii) the contract price is fixed or determinable, and (iv)collection is reasonably assured. In licensing arrangements, delivery does not occur for revenue recognition purposes until the license term begins. Nonrefundable upfront fees received in exchange for products delivered or services performed that do not represent the culmination of a separate earnings process will be deferred and recognized over the term of the agreement using the straight line method or another method if it better represents the timing and pattern of performance. Since its inception, all of the Company’s revenues have been from multiple research grants. For the three and nine months ended July 31, 2013 and 2012, the Company did not receive any revenue from such grants.

For revenue contracts that contain multiple elements, revenue arrangements with multiple deliverables are divided into separate units of accounting if the delivered item has value to the customer on a standalone basis and there is objective and reliable evidence of the fair value of the undelivered item.

Cash

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of July 31, 2013 and October 31, 2012, the Company did not have any cash equivalents.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits.

Net Loss per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the periods. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential common stock outstanding during the period. Therefore, in the case of a net loss the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share.

	As of July 31,
	2013		2012
Warrants		899,494		917,910
Stock Options		467,923		358,459
Convertible Debt (using the if-converted method)		478,695		92,759
Total		1,846,112		1,369,128

Stock Based Compensation

The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.

Stock-based compensation for directors is reflected in general and administrative expenses in the statements of operations. Stock-based compensation for employees and consultants could be reflected in research and development expenses or general and administrative expenses in the statements of operations depending on the nature of the services provided by the employees or consultants.

Fair Value of Financial Instruments

The carrying amounts of financial instruments, including cash, accounts payable and accrued expenses approximated fair value as of the balance sheet date presented, because of the relatively short maturity dates on these instruments. The carrying amounts of the financing arrangements issued approximate fair value as of the balance sheet date presented, because interest rates on these instruments approximate market interest rates after consideration of stated interest rates, anti-dilution protection and associated warrants.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used the Black Scholes valuation model which approximated the binomial lattice options pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months of the balance sheet date.

Hybrid Financial Instruments

For certain hybrid financial instruments, the Company elected to apply the fair value option to account for these instruments. The Company made an irrevocable election to measure such hybrid financial instruments at fair value in their entirety, with changes in fair value recognized in earnings at each balance sheet date. The election may be made on an instrument by instrument basis.

Debt Discount and Amortization of Debt Discount

Debt discount represents the fair value of embedded conversion options of various convertible debt instruments and attached convertible equity instruments issued in connection with debt instruments. The debt discount is amortized over the earlier of (i) the term of the debt or (ii) conversion of the debt, using the straight-line method which approximates the interest method. The amortization of debt discount is included as a component of other expenses in the accompanying statements of operations.

Recent Accounting Pronouncements

In July 2012, the FASB issued ASU 2012-02, “Intangibles-Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment." This ASU simplifies how entities test indefinite-lived intangible assets for impairment which improve consistency in impairment testing requirements among long-lived asset categories. These amended standards permit an assessment of qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. For assets in which this assessment concludes it is more likely than not that the fair value is more than its carrying value, these amended standards eliminate the requirement to perform quantitative impairment testing as outlined in the previously issued standards. The guidance is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, early adoption is permitted. The adoption of this standard did not have a material impact on the Company’s financial position, results of operations or cash flows.

In February 2013, the FASB issued ASU No. 2013-02, "Reporting of Amounts Reclassified Out of Other Comprehensive Income". ASU 2013-02 finalized the reporting for reclassifications out of accumulated other comprehensive income, which was previously deferred, as discussed below. The amendments do not change the current requirements for reporting net income or other comprehensive income in financial statements. However, they do require an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. An entity is also required to present on the face of the financials where net income is reported or in the footnotes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income, but only if the amount reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. Other amounts need only be cross-referenced to other disclosures required that provide additional detail of these amounts. The amendments in this update are effective for reporting periods beginning after December 15, 2012. Early adoption is permitted. The adoption of this standard did not have a material impact on the Company’s financial position, results of operations or cash flows.

In March 2013, the FASB issued ASU No. 2013-05, “Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity.” This ASU addresses the accounting for the cumulative translation adjustment when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity. The guidance outlines the events when cumulative translation adjustments should be released into net income and is intended by the FASB to eliminate some disparity in current accounting practice. This ASU is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this standard did not have a material impact on the Company’s financial position, results of operations or cash flows.

In March 2013, the FASB issued ASU 2013-07, “Presentation of Financial Statements (Topic 205): Liquidation Basis of Accounting.” The amendments require an entity to prepare its financial statements using the liquidation basis of accounting when liquidation is imminent. Liquidation is imminent when the likelihood is remote that the entity will return from liquidation and either (a) a plan for liquidation is approved by the person or persons with the authority to make such a plan effective and the likelihood is remote that the execution of the plan will be blocked by other parties or (b) a plan for liquidation is being imposed by other forces (for example, involuntary bankruptcy). If a plan for liquidation was specified in the entity’s governing documents from the entity’s inception (for example, limited-life entities), the entity should apply the liquidation basis of accounting only if the approved plan for liquidation differs from the plan for liquidation that was specified at the entity’s inception. The amendments require financial statements prepared using the liquidation basis of accounting to present relevant information about an entity’s expected resources in liquidation by measuring and presenting assets at the amount of the expected cash proceeds from liquidation. The entity should include in its presentation of assets any items it had not previously recognized under U.S. GAAP but that it expects to either sell in liquidation or use in settling liabilities (for example, trademarks). The amendments are effective for entities that determine liquidation is imminent during annual reporting periods beginning after December 15, 2013, and interim reporting periods therein. Entities should apply the requirements prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of this standard did not have a material impact on the Company’s financial position, results of operations or cash flows.

In July 2013, the FASB issued ASU 2013-11, “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” Under this new guidance, companies must present this unrecognized tax benefit in the financial statements as a reduction to deferred tax assets created by net operating losses or other tax credits from prior periods that occur in the same taxing jurisdiction. If the unrecognized tax benefit exceeds such credits it should be presented in the financial statements as a liability. This update is effective for annual and interim reporting periods for fiscal years beginning after December 15, 2013. The adoption of this standard did not have a material impact on the Company’s financial position, results of operations or cash flows.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying consolidated financial statements.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company will classify as income tax expense any interest and penalties. The Company has no material uncertain tax positions for any of the reporting periods presented. The Company files tax returns in U.S. federal and state jurisdictions, including New Jersey, and is subject to audit by tax authorities beginning with the year ended October 31, 2009.

PROPERTY AND EQUIPMENT

9 Months Ended

Jul. 31, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

3. PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

	July 31, 2013 (Unaudited)		October 31, 2012
Laboratory equipment	$	284,516	$	287,516
Accumulated depreciation		(223,074)		(209,448)
Net Property and Equipment	$	61,442	$	78,068

Depreciation expense for the three and nine months ended July 31, 2013 and 2012 and the period from March 1, 2002 (inception) to July 31, 2013 was $4,442, $13,626, $4,592, $9,184, and $223,074, respectively.

INTANGIBLE ASSETS

9 Months Ended

Jul. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets Disclosure [Text Block]

4. INTANGIBLE ASSETS

Under the Penn license agreements, the Company is billed actual patent expenses as they are passed through from Penn and are billed directly from the Company’s patent attorney. The following is a summary of intangible assets as of the end of the following fiscal periods:

	July 31, 2013 (Unaudited)		October 31, 2012
License	$	651,992	$	651,992
Patents		2,626,365		2,422,409
Total intangibles		3,278,357		3,074,401
Accumulated amortization		(778,566)		(660,646)
Intangible Assets	$	2,499,791	$	2,413,755

The expirations of the existing patents range from 2014 to 2023 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. No patent applications with future value were abandoned or expired and charged to expense in the three and nine months ended July 31, 2013 or 2012. Amortization expense for licensed technology and capitalized patent cost is included in general and administrative expenses and aggregated $40,109, $117,920 and $37,435, $109,858 for the three and nine months ended July 31, 2013 and 2012 and $860,562 for the period from March 1, 2002 (inception) to July 31, 2013, respectively.

Estimated amortization expense for the next five years is as follows:

Year ended October 31,
2013, remainder	$	35,000
2014		140,000
2015		140,000
2016		140,000
2017		140,000

SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE

9 Months Ended

Jul. 31, 2013

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

5. SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE

	July 31/ 2013 (Unaudited)		October 31, 2012
October 2011 Note Financing	$	-	$	58,824
December 2011 Note Financing		-		131,928
May 2012 Note Financing		83,333		588,313
Bridge Notes		62,882		185,758
JMJ Financial		995,166		73,590
Hanover Holdings Note		-		362,791
Magna		-		333,086
Chris French		-		25,950
Asher		507,830		150,687
Yvonne Paterson		-		103,804
James Patton		-		78,909
Redwood Management LLC		388,751		-

Total Convertible Notes		2,037,962		2,093,640

Unamortized discount – Original Issue Discount (OID)		-		(4,541)

Current Portion of Convertible Notes	$	2,037,962	$	2,089,099

Convertible Notes payable consist of the following:

October 2011 Note Financing

The notes issued by the Company in the offering completed in October 2011, which it refers to as the October 2011 Notes, matured on October 31, 2012. At October 31, 2012, there was one remaining October 2011 Note with an outstanding principal balance of $58,824.

During the nine months ended July 31, 2013, pursuant to the terms of an Assignment Agreement, the Company delivered a convertible note, which we refer to as the Second Magna Exchange Note, to Magna Group, LLC, an affiliate of Hanover, which it refers to as Magna, in an aggregate principal amount of $58,824, convertible into shares of common stock, which bears interest at a rate of 6% per annum, which interest accrues, but does not become payable until maturity.

During the nine months ended July 31, 2013, the Company converted the $58,824 in principal into 18,224 shares of common stock at conversion prices ranging from $3.16 to $3.25, recording non-cash expense of approximately $70,000 to the loss on retirement account, on the statement of operations, for the difference between the amount of the principal converted and the fair value of the shares issued as a result of the conversion.

As of July 31, 2013, there were no outstanding October 2011 Notes.

December 2011 Note Financing

At October 31, 2012, there was one remaining note that was issued by the Company in the offering completed in December 2011, which it refers to as the December 2011 Note, with an outstanding principal balance of $158,824, having an unamortized debt discount of $26,896.

During the nine months ended July 31, 2013, pursuant to the terms of an Assignment Agreement, the Company delivered a convertible note to Magna in an aggregate principal amount of $170,589 (including the above $158,824 and a junior subordinated convertible promissory note in the amount of $11,765), convertible into shares of common stock, which bears interest at a rate of 6% per annum, which interest accrues, but does not become payable until maturity.

Accretion of the discount was $26,896 for the three months ended January 31, 2013, resulting in the December 2011 Note being recorded at its principal value of $158,824, on the balance sheet, prior to its assignment. During the nine months ended July 31, 2013, the Company converted the $170,589 in principal into 48,888 shares of its common stock at a conversion price of $3.49, recording non-cash expense of approximately $104,000 to the loss on retirement account, on the statement of operations, for the difference between the amount of principal converted and the fair value of the shares issued as a result of the conversion.

As of July 31, 2013, there were no outstanding December 2011 Notes.

May 2012 Note Financings

Effective May 14, 2012, the Company entered into a Note Purchase Agreement, which it refers to as the May 2012 Notes, in which investors acquired $953,333 of convertible promissory notes for an aggregate purchase price of approximately $715,000 in cash, representing an original issue discount of 25%. The May 2012 Notes are convertible into shares of common stock at $18.75 per share. Additionally, investors received warrants, which the Company refers to as the May 2012 Warrants, to purchase such number of shares of common stock equal to 50% of the number of shares of our common stock that would be issuable upon conversion of their May 2012 Notes at an exercise price of $18.75 per share. The May 2012 Notes matured on May 18, 2013. The Company may redeem the May 2012 Notes under certain circumstances. The May 2012 Warrants are exercisable at any time on or before May 18, 2017. The May 2012 Warrants may be exercised on a cashless basis under certain circumstances. As of July 31, 2013 the conversion price of the May 2012 Notes was $3.16 due to the anti-dilution provisions contained therein and the exercise price of the May 2012 Warrants was $10.625 as a result of the price reset provisions contained therein.

The Company elected to apply the fair-value option to account for the May 2012 Notes and has recorded the May 2012 Notes at a fair value of $454,680 upon issuance. Unrealized losses on the mark-to-market of the May 2012 Notes which amounted to $266,332 for the period from the date of issuance or May, 14, 2012 through July 31, 2013 were recognized as a non-cash expense in the changes in fair value account on the statement of operations. Accretion of the discount, related to the original fair value of the associated warrants, was recognized through interest expense, amounting to $291,400 for the period from the date of issuance or May 14, 2012 through July 31, 2013.

In addition, as a result of the reset provisions discussed above, the May 2012 Warrants, which have been recorded at a fair value of $291,400 on May 14, 2012, are being reflected as a warrant liability as of the date of issuance. At October 31, 2012, the warrant liability amounted to $112,487. As of July 31, 2013, the warrant liability amounted to $18,426, which resulted in a non-cash income of $65,294 for the three months ended July 31, 2013 and non-cash expense of $7,717 for the nine months ended July 31, 2013, being recorded in the changes in fair value account on the statement of operations.

During the nine months ended July 31, 2013, the Company converted $870,000 in principal into 275,240 shares of its common stock at a conversion price of $3.16, recording non-cash expense of approximately $25,200 to the loss on retirement account, on the statement of operations, for the difference between the amount of the principal converted and the fair value of the shares issued as a result of the conversion.

As of July 31, 2013, approximately $83,000 in principal remained outstanding on one May 2012 Note. As of July 31, 2013, this May 2012 Note, which matured on May 18, 2012, was recorded on the balance sheet, as a current liability, at its remaining principal value of $83,333.

On August 8 , 2013, the remaining May 2012 Note holder converted $83,333 in principal into 26,371 shares of common stock at a conversion rate of $3.16.

Currently, there are no remaining May 2012 Notes. (See Note 14: Subsequent Events for more information on these conversions after the balance sheet date).

Junior Subordinated Convertible Promissory Notes

The Company refers to all Junior Subordinated Convertible Promissory Notes as “Bridge Notes”.

The Bridge Notes are convertible into shares of the Company’s common stock at a fixed exercise price. For every dollar invested in the Company’s Bridge Notes, each investor received warrant coverage ranging from approximately 23% to 75%, subject to adjustments upon the occurrence of certain events as more particularly described below and in the form of warrant. As of October 31, 2012, substantially all of the Bridge Warrants had an exercise price of $18.75 per share. The Bridge Notes may be prepaid in whole or in part at the option of the Company without penalty at any time prior to the maturity date. The warrants may be exercised on a cashless basis under certain circumstances.

As of October 31, 2012, the Company had approximately $186,000 in principal outstanding on its junior subordinated convertible promissory notes with maturity dates ranging to May 12, 2012.

During the three and nine months ended July 31, 2013, pursuant to the terms of various Assignment Agreements, the Company delivered convertible notes to Magna in aggregate principal amounts of $170,589 (including $11,765 of junior subordinated convertible promissory notes plus the above December 2011 Note in the principal amount of $158,824) and $111,111(consisting of one junior subordinated convertible promissory note), convertible into shares of common stock, which bears interest at a rate of 6% per annum, which interest accrues, but does not become payable until maturity. The Company converted the exchange note, which it refers to as the Third Magna Exchange Note, in the principal amount of $111,111 into 34,241 shares of its common stock at a conversion price of $3.25 per share, recording non-cash expense of approximately $106,000 to the loss on retirement account, on the statement of operations, for the difference between the amount of the principal converted and the fair value of the shares issued as a result of the conversion.

As of July 31, 2013, approximately $63,000 in principal remained outstanding on the junior unsubordinated convertible promissory notes, with maturity dates ranging to October 22, 2011. These notes are currently in default and are recorded as current liabilities on the balance sheet at July 31, 2013.

JMJ Financial

On August 27, 2012, in a private placement pursuant to a Note Purchase Agreement, the Company issued JMJ Financial a convertible promissory note in the aggregate principal amount of $100,000 for a purchase price of $100,000, which it refers to as the JMJ August 2012 Note. As of October 31, 2012, the JMJ August 2012 Note remained outstanding. Due to the conversion feature into a variable number of shares, the JMJ August 2012 Note is valued at fair value at each reporting period. As of October 31, 2012, the fair value of the JMJ August 2012 Note was $73,590.

During the nine months ended July 31, 2013, the Company converted the JMJ August 2012 Note totaling $100,000 into 24,744 shares of its common stock. The Company recorded non-cash income of approximately $96,000 upon conversion. This non-cash income was recorded to the gain on retirement account, on the statement of operations, representing the difference between the fair value of the JMJ August 2012 Note, as reported on the balance sheet, and the fair value of the shares issued as a result of the conversion.

On December 28, 2012, in a private placement pursuant to a note purchase agreement, the Company issued JMJ Financial a one month convertible promissory note, which it refers to as the JMJ December 2012 Note, in the aggregate principal amount of $100,000 for a purchase price of $100,000. If repaid before January 31, 2013, the principal amount of the JMJ December 2012 Note would be $125,000. If the JMJ December 2012 Note was to be rolled into a future financing, the principal amount would be $115,000.

On April 26, 2013, in a private placement, the Company issued JMJ Financial a convertible promissory note (“JMJ April 2013 Note”). The face amount of the note reflects an aggregate principal amount of $800,000 for total consideration of $720,000 (or a 10% original issue discount). As of April 26, 2013, the Company had only borrowed $425,000 from JMJ Financial under this convertible promissory note. JMJ Financial paid $300,000 in cash and exchanged the JMJ December 2012 Note with an aggregate principal amount of $125,000 as consideration for the note. The exchange was analyzed and management concluded that the exchange qualifies for modification accounting. On June 27, 2013, the Company borrowed an additional $100,000 under the convertible promissory note. .JMJ Financial has no obligation to lend the Company the remaining $195,000 of available principal amount under the note and may never do so. The Company has no obligation to pay JMJ Financial any amounts on the unfunded portion of the note. The Company may not prepay any portion of the note without JMJ Financial’s consent.

The convertible promissory note matures April 26, 2014 and, in addition to the 10% original issue discount, provides for payment of a one-time interest charge of 5% on funded amounts. The convertible promissory note is convertible at any time, in whole or in part, at JMJ Financial’s option into shares of the Company’s common stock at the lesser of $8.75 or 70% of the average of the lowest two closing prices in the 20-day pricing period preceding a conversion. However, at no time will JMJ Financial be entitled to convert any portion of the note to the extent that after such conversion, JMJ Financial (together with its affiliates) would beneficially own more than 4.99% of the Company’s outstanding shares of common stock as of such date. The Company agreed to reserve at least 160,000 shares of its common stock for conversion of the note. The note also provides for penalties and rescission rights if the Company does not deliver shares of its common stock upon conversion within the required timeframes.

The convertible promissory note includes customary event of default provisions, and provides for a default rate of the lesser of 18% or the maximum permitted by law. Upon the occurrence of an event of default, the lender may require the Company to pay in cash the “Mandatory Default Amount” which is defined in the note to mean the greater of (i) the outstanding principal amount of the note plus all interest, liquidated damages and other amounts owing under the note, divided by the conversion price on the date payment of such amount is demanded or paid in full, whichever is lower, multiplied by the volume-weighted-average price, or VWAP, on the date payment of such amount is demanded or paid in full, whichever has a higher VWAP, or (ii) 150% of the outstanding principal amount of the note plus 100% of all interest, liquidated damages and other amounts owing under the note.

The Company also granted JMJ Financial the right, at its election, to participate in the next public offering of its securities by exchanging, in whole or in part, the funded portion of this note for a subscription to such public offering in an amount equal to 125% of the sum of the funded portion of the principal amount of being exchanged plus all accrued and unpaid interest, liquidated damages, fees, and other amounts due on such exchanged principal amount. However, the note was subsequently amended in September 2013 to remove this right. See Note 14 Subsequent Events. If the Company completes a public offering of $10,000,000 or more, JMJ Financial has the right, at its election, to require repayment of the note, in whole or in part, in amount equal to 125% of the sum of the funded principal amount being repaid plus all accrued and unpaid interest liquidated damages, fees, and other amounts due on such principal amount. In September 2013, this note was amended to lower this threshold to $5,000,000 in connection with the sale of the new convertible promissory note to JMJ Financial. See Note 14 - Subsequent Events.

At July 31, 2013, the outstanding JMJ April 2013 Note was recorded on the balance sheet at its fair value of $995,166.

Hanover Holdings Notes

On September 19, 2012, in a private placement pursuant to a Note Purchase Agreement, the Company issued Hanover Holdings I, LLC, which the Company refers to as Hanover, a convertible promissory note in the aggregate principal amount of $132,500, for a purchase price of $132,500, which the Company refers to as the Initial Hanover PIPE Note. On October 19, 2012, in a private placement pursuant to a note purchase agreement, the Company issued Hanover a convertible promissory note in the aggregate principal amount of $132,500, for a purchase price of $132,500, which the Company refers to as the Second Hanover PIPE Note, which, together with the Initial Hanover PIPE Note the Company refers to as the Hanover PIPE Notes.

On December 6, 2012, in a private placement pursuant to a note purchase agreement, the Company issued Hanover a convertible promissory note in the aggregate principal amount of $100,000 for a purchase price of $100,000, which the Company refers to as the Hanover December 2012 Note. The Hanover December 2012 Note bears interest at a rate of 12% per annum, which interest accrues, but does not become payable until maturity or acceleration of the principal of such Hanover December 2012 Note. The Hanover December 2012 Note is convertible into shares of the Company’s common stock at a conversion price of $3.75 per share. On December 5, Hanover exchanged the Initial Hanover PIPE Notes for convertible notes in the form of the Hanover December 2012 Note in all material respects (other than date of issuance, exchange date, the maturity date of May 19, 2013 solely with respect to the exchanged Hanover PIPE Note issued in exchange for the Initial Hanover PIPE Note and the maturity date of June 19, 2013 solely with respect to the exchanged Hanover PIPE Note issued in exchange for the Second Hanover PIPE Note) that also are convertible into shares of its common stock at a conversion price of $3.75 per share, which the Company refers to as the Exchanged Hanover PIPE Notes. In addition, on December 6, 2012, the Company issued Hanover a convertible promissory note in the aggregate principal amount of $100,000, which the Company refers to as the Hanover December 2012 Note. Each of the Hanover December 2012 Note and the Exchanged Hanover PIPE Notes are subject to limitations on conversion if after giving effect to such conversion Hanover would beneficially own more than 4.99% of the Company’s common stock.

Due to the fixed conversion price of $3.75, the Company reversed fair value adjustments taken in the period ended October 31, 2012 resulting in the Hanover PIPE Notes being recorded on the balance sheet at principal value. Then, the Company recorded beneficial conversion features in the aggregate principal amount of $122,092 as a discount to these notes. Accretion of the discounts amounted to $10,055 and $122,092 for the three and nine months ended July 31, 2013, respectively.

During the nine months ended July 31, 2013, the note-holder converted principal of $365,000 into 97,333 shares of the Company’s common stock at a conversion rate of $3.75 per share. During the nine months ended July 312013, the Company recognized interest expense of approximately $72,000 in order to accrete the unamortized debt discount back to the notes’ principal through the dates of conversion.

As of July 31, 2013, there were no remaining Hanover Notes.

Magna Note

As of October 31, 2012, the Magna Exchange Note was recorded at a fair value of $333,086 on the balance sheet.

During the nine months ended July 31, 2013, Magna converted the remaining approximately $300,000 in principal into 80,992 shares of the Company’s common stock at prices ranging from $3.21 to $4.14, resulting in non-cash expense for the period of approximately $44,000 resulting from the difference between the amount of principal converted and the fair value of the shares issued as a result of the conversion.

As of July 31, 2013, the Magna Exchange Note had been converted in full.

Chris French

During the nine months ended July 31, 2013, the Company converted principal of $25,000 of a note issued to Chris French plus accrued interest of approximately $633, into 4,527 shares of its common stock at a conversion price of $5.625 per share. In addition, the Company issued a warrant to acquire 2,263 shares, which expires on October 26, 2015 and revalued the warrant liability, at July 31, 2013, with an exercise price of $5.625, resulting in non-cash expense of approximately $21,000 resulting from the difference between the fair value of the note as shown on the balance sheet plus accrued interest to-date and the fair value of the shares issued as a result of the conversion.

As of July 31, 2013, this note no longer remained outstanding.

Asher

On September 11, 2012, in a private placement pursuant to a Note Purchase Agreement, the Company issued Asher Enterprises, Inc, which it refers to as Asher, a convertible promissory note in the aggregate principal amount of $103,500, for a purchase price of $100,000, which it refers to as the Asher Note. The Asher Note bears interest at a rate of 8%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Asher Note. The Asher Note is convertible into shares of the Company’s common stock at a conversion price equal to 61% of the arithmetic average of the five lowest closing trading prices for the common stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Asher Note matured on June 13, 2013, nine months from its issuance date. The Asher Note was able to be converted by Asher, at its option, in whole or in part and included a limitation on conversion, which provided that at no time would Asher be entitled to convert any portion of the Asher Note, to the extent that after such conversion, Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock of the Company as of such date.

Unrealized losses on the mark-to-market of the Asher Note which amounted to $47,187, for the period from the date of issuance were recorded as non-cash expense for the period ended October 31, 2012. During the nine months ended July 31, 2013, Asher converted principal of $103,500 and accrued interest into approximately 16,439 shares of the Company’s common stock at a conversion rate of approximately $6.50/share.

On November 12, 2012, in a private placement pursuant to a note purchase agreement, the Company issued Asher a convertible promissory note in the aggregate principal amount of $153,500, for a purchase price of $150,000, which it refers to as the Second Asher Note. The Second Asher Note bears interest at a rate of 8%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Second Asher Note. The Second Asher Note is convertible into shares of the Company’s common stock at a conversion price equal to 65% of the arithmetic average of the five lowest closing trading prices for the common stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Second Asher Note matured on August 14, 2013, nine months from its issuance date. The Second Asher Note may be converted by Asher, at its option, in whole or in part and included a limitation on conversion, which provides that at no time would Asher be entitled to convert any portion of the Second Asher Note, to the extent that after such conversion, Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock of the Company as of such date.

Unrealized gains on the mark-to-market of the Second Asher Note which amounted to $63,980, for the period from the date of issuance were recorded as non-cash income for the period ended July 31, 2013. During the three months ended July 31, 2013, Asher converted principal of $153,500 and accrued interest into approximately 44,161 shares of the Company’s common stock at a conversion prices ranging from $3.43/share to $3.90/share.

On May 1, 2013, in a private placement pursuant to a note purchase agreement, the Company issued Asher a convertible promissory note in the aggregate principal amount of $203,500, for a purchase price of $200,000, which it refers to as the Third Asher Note. The Third Asher Note bears interest at a rate of 8%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Third Asher Note. The Third Asher Note is convertible into shares of the Company’s common stock at a conversion price equal to 65% of the arithmetic average of the five lowest closing trading prices for the common stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Third Asher Note matures on February 3, 2014, nine months from its issuance date. The Third Asher Note may be converted by Asher, at its option, in whole or in part and included a limitation on conversion, which provides that at no time would Asher be entitled to convert any portion of the Third Asher Note, to the extent that after such conversion, Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock of the Company as of such date.

Unrealized losses on the mark-to-market of the Third Asher Note which amounted to $131,462 for the period from the date of issuance were recorded as non-cash expense for the period ended July 31, 2013. As of July 31, 2013, the Third Asher Note was recorded on the balance sheet at its fair value of $334,962.

On July 12, 2013, in a private placement pursuant to a note purchase agreement, the Company issued Asher a convertible promissory note in the aggregate principal amount of $103,500, for a purchase price of $100,000, which it refers to as the Fourth Asher Note. The Fourth Asher Note bears interest at a rate of 8%, which interest accrues, but does not become payable until maturity or accelerations of the principal of the Fourth Asher Note. The Fourth Asher Note is convertible into shares of the Company’s common stock at a conversion price equal to 65% of the arithmetic average of the five lowest closing trading prices for the common stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Fourth Asher Note matures on April 16, 2014, nine months from its issuance date. The Fourth Asher Note may be converted by Asher, at its option, in whole or in part and included a limitation on conversion, which provides that at no time will Asher be entitled to convert any portion of the Fourth Asher Note, to the extent that after such conversion, Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock of the Company as of such date.

Unrealized losses on the mark-to-market of the Fourth Asher Note which amounted to $69,368, for the period from the date of issuance were recorded as non-cash expense for the period ended July 31, 2013. As of July 31, 2013, the Fourth Asher Note was recorded on the balance sheet at its fair value of $172,868.

Yvonne Paterson

During the nine months ended July 31, 2013, the Company converted principal of $100,000 of a note issued to Yvonne Paterson plus accrued interest of approximately $2,532, into 18,107 shares of its common stock at a conversion price of $5.625 per share. In addition, the Company issued a warrant to acquire 9,054 shares, which expires on October 26, 2015 and revalued the warrant liability, at July 31, 2013, with an exercise price of $5.625, resulting in non-cash expense of approximately $32,000 resulting from the difference between the fair value of the note as shown on the balance sheet plus accrued interest to-date and the fair value of the shares issued as a result of the conversion.

As of July 31, 2013, this note no longer remained outstanding.

James Patton

On August 2, 2012, in a private placement pursuant to a Note Purchase Agreement, the Company issued Dr. James Patton, a member of our board of directors, a convertible promissory note, which it refers to as the Patton Note in the principal amount of $66,667 for a purchase price of $50,000. The Patton Note was issued with an original issue discount of 25%. Dr. Patton paid $0.75 for each $1.00 of principal amount of the Patton Note purchased. The Patton Note is convertible into shares of the Company’s common stock at a per share conversion price equal to $3.16 and is subject to “full ratchet” anti-dilution protection upon certain equity issuances below $3.16 per share (as may be further adjusted). Additionally, Dr. Patton received a warrant, which the Company refers to as the Patton Warrant, to purchase such number of shares of its common stock equal to 50% of such number of shares of common stock issuable upon conversion of the Patton Note at an exercise price of $10.625 per share. The Patton Note matured on August 2, 2013 and was redeemable under certain circumstances. The Patton Warrant is exercisable at any time on or before August 2, 2017 and may be exercised on a cashless basis under certain circumstances. The Patton Note and the Patton Warrant each include a limitation on conversion or exercise, as applicable, which provides that at no time will Dr. Patton be entitled to convert any portion of the Patton Note or Patton Warrant, to the extent that after such conversion or exercise, as applicable, Dr. Patton (together with his affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock as of such date.

As of July 31, 2013, the Patton Warrants had a fair value of $2,304, resulting in non-cash income of approximately $8,400 and $5,700 for the three and nine months ended July 31, 2013, respectively.

During the three months ended July 31, 2013, the Company converted the principal amount of the Patton Note, of $66,667, into 21,092 shares at a conversion price of $3.16. The Company recorded non-cash income of approximately $94,000 and $3,590 for the three and nine months ended July 31, 2013, respectively.

Accretion of the discount amounted to $3,355, for the three and nine months ended July 31, 2013.

As of July 31, 2013, the Patton Note no longer remained outstanding and the number of shares of common stock to be acquired upon the exercise of the Patton Warrant remained at 1,778.

Redwood Management LLc

On June 21, 2013, the Company entered into a bridge financing arrangement with Redwood Management, LLC (“Redwood”), an accredited investor, for which Aegis Capital Corp. acted as placement agent and received an 8% fee based on the consideration paid to to the Company. Accordingly, on June 21, 2013, the Company entered into a Securities Purchase Agreement with Redwood Management LLC, which it refers to as Redwood, and in a private placement thereunder issued Redwood a convertible promissory note in the aggregate principal amount of $277,777, for a purchase price of $250,000 ( or a 10% original issue discount), which it refers to as the Redwood Note. The Redwood Note bears interest at a rate of 5%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Redwood Note. The Redwood Note is convertible into shares of the Company’s common stock at a conversion price equal to the lesser of (i) $6.25, or (ii) 70% of the ten day average value weighted average price (“VWAP”) for the ten trading days immediately preceding the conversion date. The Redwood Note matures on December 30, 2013, six months from its issuance date. The Redwood Note may be converted by Redwood, at its option, in whole or in part. The Redwood Note includes a limitation on conversion, which provides that at no time will Redwood be entitled to convert any portion of the Redwood Note, to the extent that after such conversion, Redwood (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock as of such date.

The Company agreed to reserve at least 2.5 times the number of shares of its common stock actually issuable upon full conversion of the Redwood Note, and not to take certain actions without Redwood’s consent and granted Redwood the right, at its election, to participate in future financings subject to certain limited exceptions. So long as the Company is not in default, and provided it has given 20 days prior written notice, it may prepay the Redwood Note in full at any time at a premium of 110% of the amount owed (which multiple increases 4 months after the issuance date). In addition, if the Company completes a financing of $7,000,000 or more, Redwood has the right, at its election, to require the Company to repay the Redwood Note in full on the closing date of such financing on the same payment terms as noted in the preceding sentence. The Redwood Note includes customary event of default provisions, and provide for a default rate of 14%.

Unrealized losses on the mark-to-market of the Redwood Note which amounted to $110,972, for the period from the date of issuance were recorded as non-cash expense for the period ended July 31, 2013. As of July 31, 2013, the Redwood Note was recorded on the balance sheet at its fair value of $388,751.

NOTES PAYABLE- FORMER OFFICER:	9 Months Ended
NOTES PAYABLE- FORMER OFFICER:	Jul. 31, 2013
Notes Payable Officer [Abstract]
Notes Payable Officer [Text Block]	6. NOTES PAYABLE- FORMER OFFICER: Moore Notes The Company has agreed to sell senior promissory notes, which it refers to as the Moore Notes, to Mr. Moore, a Director of the Company and its former chief executive officer, from time to time, under an agreement which we refer to as the Moore Agreement. The Moore Notes bear interest at the rate of 12% per annum. Currently, under the terms of the amended and restated Moore Notes, the maturity date is the earlier of (i) the date of consummation of an equity financing in an amount of $6.0 million or more or (ii) the occurrence of any event of default as defined in the Moore Notes. As of October 31, 2012, the Company owed Mr. Moore approximately $477,000 in principal and interest under the Moore Notes. For the nine months ended July 31, 2013, Mr. Moore loaned the Company $11,200 under the Moore Notes. The Company paid Mr. Moore $85,700 principal on the Moore Notes for the nine months ended July 31, 2013. For the three and nine months ended July 31, 2013 as well as the period from inception, the Company recorded interest expense of $7,198, 24,841, $324,862 respectively. As of July 31, 2013 and October 31, 2012, respectively, the Company was not in default under the terms of the Moore Agreement. The Company intends to repay Mr. Moore when funds are sufficiently available. As of July 31, 2013, the Company owed Mr. Moore approximately $428,000 in principal and interest under the Moore Notes. In August 2013, Mr. Moore resigned as Chairman of the Board of Directors and as Chief Executive Officer and entered into a consulting agreement with the Company, which provided for a $100,000 payment towards the Moore Notes in the event the Company closes a financing greater than $5,000,000 during the initial term of the consulting agreement (which amount may be increased to $429,076.59 at the Company’s discretion if the financing exceeds $15,000,000). The consulting agreement also provides that if the Company closes any financing equal to or greater than $15,000,000 but does not fully satisfy its cumulative outstanding financial obligations, if any, to Mr. Moore as described above, then the Company must pay the remaining balance of any such outstanding financial obligations on the earlier of: (i) six months from the date of closing; or (ii) upon the completion of an underwritten financing (not currently contemplated). See Note 14 – Subsequent Events.

NOTES PAYABLE-OTHER:	9 Months Ended
NOTES PAYABLE-OTHER:	Jul. 31, 2013
Other Notes Payable [Abstract]
Other Notes Payable [Text Block]	7. NOTES PAYABLE-OTHER: JLSI, LLC On July 21, 2012, the Company received $250,000 from JLSI, LLC in return for issuing a promissory note in the principal amount of $250,000, which bears interest at 33% per annum, compounded annually and which matured on December 31, 2012 (“July 2012 Note”). The Company has recorded approximately $37,000 in interest related to this promissory note, through December 31, 2012. On March 10, 2013 the Company entered into an Exchange Agreement with JLSI, LLC to exchange the July 2012 Note in the principal amount of $250,000 plus interest of approximately $37,000 for common stock, par value $.001 per share . On December 31, 2012 the parties agreed to prepare the Exchange Agreement with a fixed conversion price of $3.75 per share, the market closing price of the Company’s common stock on December 31, 2012. The Company issued 76,491 shares during the second fiscal quarter of 2013 to settle the note and interest. As of July 31, 2013, this note no longer remained outstanding.

LONG-TERM CONVERTIBLE NOTE	9 Months Ended
LONG-TERM CONVERTIBLE NOTE	Jul. 31, 2013
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	8. LONG-TERM CONVERTIBLE NOTE Tonaquint Note On December 13, 2012, the Company entered into a securities purchase agreement with Tonaquint, Inc., the Tonaquint Purchase Agreement, whereby the Company issued Tonaquint a convertible promissory note for the initial principal sum of $890,000. The Company refers to this note as the Tonaquint Note. The Tonaquint Note bears interest at a rate of 8% and is due 26 months after its issue date. The Tonaquint Note can currently be converted at any time, from time to time, at the option of the holder, in whole or in part, a fixed price of $20.00 per share but is subject to adjustment if and whenever on or after six months from the issue date the Company issues shares of its common stock or other securities convertible into or exchangeable for shares of its common stock below the current conversion price of $20.00. On the closing date, Tonaquint (i) funded $400,000 in cash, (ii) issued a secured mortgage note in the principal amount of $200,000, which is referred to as Mortgage Note 1, and (iii) issued an additional secured mortgage note in the principal amount of $200,000, which is referred to as Mortgage Note 2. Mortgage Note 1 bore interest at a rate of 5% and was due on the earlier of (i) 60 days following the maturity date under the Tonaquint Note, and (ii) the later of (A) eight months after the closing date under the Tonaquint Purchase Agreement and (B) satisfaction of certain payment conditions. Mortgage Note 2 bore interest at a rate of 5% and was due on the earlier of (i) 60 days following the maturity date under the Tonaquint Note, and (ii) the later of (A) 10 months after the closing date under the Tonaquint Purchase Agreement and (B) satisfaction of certain payment conditions. Beginning in June 2013, the Company began making monthly installment payments on the Tonaquint Note as required by the terms of the note, which contemplates 18 installment payments equal to approximately $50,000. These installment payments may be made at the Company’s option in cash or in stock although they must be made in cash if certain conditions are not met. If it chooses to make installment payments in stock, then such stock will be issued at a price per share equal to 80% of the average of the 5 lowest daily closing bid prices for the common stock during the 20 consecutive trading days prior to the installment date (which is adjusted to 70% if the average of the 3 lowest volume weighted average prices during such 20-day period is less than $1.25 per share). Tonaquint has the right to receive additional shares or the Company’s common stock if the market price of the common stock is lower than the price per share on the installment date. During the three months ended July 31, 2013, the Company issued 27,583 shares of its common stock, in lieu of a cash installment payment, to satisfy $49,444 of principal and approximately $49,000 in accrued interest. This principal payment was converted into shares of common stock at a conversion price of $3.57. Unrealized losses on the mark-to-market of the Tonaquint Note, which amounted to $264,124, were recorded as a non-cash expense, for the three months ended July 31, 2013. As of July 31, 2013, the Tonaquint Note was recorded on the balance sheet at its fair value of $1,104,680. On December 13, 2012, the Company also issued Tonaquint a warrant to purchase the number of shares equal to 75% of the principal sum of $890,000 under the Tonaquint Note divided by market price as of the issue date as defined in the warrant agreement. This warrant expires 5-years from the issue date and provides for a variable exercise price per share as defined in the warrant agreement. On March 14, 2013, the Company issued 170,624 shares of its common stock resulting from the partial cashless exercise of the warrant issued to Tonaquint in December 2012. Additionally, on March 13, 2013 and March 19, 2013 Tonaquint made accelerated payments (including interest income) of $202,493 and $202,657 respectively owed to the Company under Mortgage Note 1 and Mortgage Note 2 described above. Accordingly, the Company recorded an increase to cash, interest income and short-term convertible notes received during the second fiscal quarter of 2013. Warrants to purchase up to 86,283 shares of the Company’s common stock issued to Tonaquint remain outstanding.

COMMON STOCK WARRANT LIABILITY

9 Months Ended

Jul. 31, 2013

Warrant Liability [Abstract]

Warrant Liability [Text Block]

9.COMMON STOCK WARRANT LIABILITY

Warrants

As of July 31, 2013, there were outstanding warrants to purchase 899,494 shares of the Company’s common stock with exercise prices ranging from $4.375 to $21.25 per share. Information on the outstanding warrants is as follows:

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Exchange Warrants - Nonexercisable	$	18.75		278,329	October 2014	July 2012 Exchanges
Common Stock Purchase Warrant	$	18.75		28,632	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		11,628	October 2014 - October 2015	Oct 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		17,706	May 2015 - January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		13,333	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	15.11-21.25		214,416	December 2013 -April 2015	Bridge Notes
Common Stock Purchase Warrant	$	4.375		1,333	December 2015	Stock Purchase Agreement
Common Stock Purchase Warrant	$	18.75		376	N/A	Vendor & Other
Common Stock Purchase Warrant	$	10.625-18.75		29,883	May 2014 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant		5.625-10.625		13,095	October 2015-August 2017	August – September 2012 Convertible Promissory Notes
Common Stock Purchase Warrant		3.57		86,283	December 2014	Tonaquint Promissory Note
		Subtotal:		695,014
Common Stock Purchase Warrant		TBD (1)		204,480	April 2014	Preferred Stock Agreement (4/04/2011)
		Grand Total		899,494

(1)	During December 2011, the Company unreserved for issuance shares related to the preferred stock warrants. If exercisable, exercise price means an amount per warrant share equal to the closing sale price of a share of common stock on the applicable tranche notice date.

As of October 31, 2012, there were outstanding warrants to purchase 802,580 shares of the Company’s common stock with exercise prices ranging from $6.625 to $21.25 per share. Information on the outstanding warrants is as follows:

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Exchange Warrants- Nonexercisable	$	18.75		278,329	October 2014	July 2012 Warrant Exchanges
Common Stock Purchase Warrant	$	18.75		28,632	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		11,628	October 2014-October 2015	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		17,706	January 2015-January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		22,222	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	14.95-21.25		198,036	January 2013-April 2015	Bridge Notes
Common Stock Purchase Warrant	$	18.75		376	N/A	Vendor & Other
Common Stock Purchase Warrant	$	18.75		29,883	May 2014 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant		6.625-18.75		11,288	October 2015-August 2017	August – September 2012 Convertible Promissory Notes
		Subtotal:		598,100
Common Stock Purchase Warrant		TBD (1)		204,480	April 2014	Preferred Stock Agreement (4/04/2011)
		Grand Total		802,580

(1)

During December 2011, the Company unreserved for issuance shares related to the preferred stock warrants. If exercisable, exercise price means an amount per warrant share equal to the closing sale price of a share of common stock on the applicable tranche notice date.

At both July 31, 2013 and October 31, 2012, the Company had approximately 122,000 and 121,000 of its outstanding warrants, respectively, classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholders’ equity section of the balance sheet. Its equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions.

As of July 312013, the Company had approximately 777,000 of its total approximately 899,000 outstanding warrants classified as liability warrants (common stock warrant liability). The fair value of the warrant liability, as of July 31, 2013 was approximately $0.7 million. At October 31, 2012, the Company had approximately 682,000 of its total approximately 803,000 outstanding warrants classified as liability warrants (common stock warrant liability). The fair value of the warrant liability, as of October 31, 2012, was approximately $0.4 million. In fair valuing the warrant liability, at July 31, 2013 and October 31, 2012, the Company used the following inputs in its Black-Scholes Model (BSM Model):

	(Unaudited) July 31, 2013			October 31, 2012

Exercise Price:	$	4.375-21.25		$	6.625-21.25

Stock Price		3.50			5.625

Expected Term:		153-1588 days			81-1736 days

Expected Volatility		93.73%-153.00	%		66.51%-146.78	%

Risk Free Rate:		.08%-.0995	%		0.09-.056	%

Warrant Liability

As of July 31, 2013, the Company had approximately 777,000 of its total approximately 899,000 warrants classified as liabilities (liability warrants). Of these 777,000 liability warrants, approximately 499,000 warrants are outstanding and 278,000 warrants are exchange warrants – nonexercisable. The Company utilizes the BSM Model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. Approximately 124,000 of the Company’s 804,000 liability warrants are subject to anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the common stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. - the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported in the statement of operations.

As of July 31, 2013 and October 31, 2012, the fair value of the warrant liability was approximately $736,000 and $434,000, respectively. For the three months ended July 31, 2013 and 2012, the Company reported income of approximately $1.8 million and $1.7 million, respectively due to changes in the fair value of the warrant liability. For the nine months ended July 31, 2013 and 2012, the Company reported expense of approximately $1.1 million and income of approximately $4.9 million, respectively, due to changes in the fair value of the warrant liability.

Exercise of Warrants

During the nine months ended July 31, 2013, an accredited investor exercised 8,889 warrants at an exercise price of $10.625, resulting in net proceeds to the Company of $94,444. During the nine months ended July 31, 2012, investors in the Company exercised 21,961 warrants at a price of $18.75 per share, resulting in total proceeds to the Company of approximately $412,000.

Warrants with Anti-Dilution Provisions

Some of the Company’s warrants (approximately 124,000) contain anti-dilution provisions originally set at $25.00 with a term of five years. As of July 31, 2013, these warrants had an exercise price of approximately $15.11. As of October 31, 2012, these warrants had an exercise price of approximately $18.70. If the Company issues any common stock , except for exempt issuances as defined in the warrant for consideration less than the exercise price then the exercise price and the amount of warrant shares available would be adjusted to a new price and amount of shares per the “ weighted average” formula included in the warrant. For the three months ended July 31, 2013, this anti-dilution provision required the Company to issue approximately 10,000 additional warrant shares; and the exercise price to be lowered to a de minimis amount ($15.11). Any future financial offering or instrument issuance below the current exercise price will cause further anti-dilution and re-pricing provisions in approximately 124,000 of its total outstanding warrants.

For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company utilized different exercise prices of $15.11 and $12.50, weighting the possibility of warrants being exercised at $15.11 between 40% and 50% and warrants being exercised at $12.50 between 60% and 50%.

As of July 31, 2013, there were outstanding warrants to purchase 621,165 shares of the Company’s common stock and exchange warrants - nonexercisable to purchase 278,329 shares of the Company’s common stock with exercise prices ranging from $4.375 to $21.25 per share.

STOCK OPTIONS:

9 Months Ended

Jul. 31, 2013

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Stock Options Disclosure [Text Block]

10. STOCK OPTIONS:

The Company has one active stock and cash-based incentive plan, the 2011 Omnibus Incentive Plan, which it refers to as the Incentive Plan, pursuant to which the Company has granted stock options to executive officers, directors, employees and consultants. The Incentive Plan was adopted on August 22, 2011 and approved by the stockholders on September 27, 2011. An aggregate of 160,000 shares of the Company’s common stock (subject to adjustment by the Compensation Committee of the Board) are reserved and available for delivery under the Incentive Plan. On August 13, 2012, at the Company’s annual meeting, stockholders ratified and approved an amendment to our Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan to 520,000. As of July 31, 2013, the Company had granted 271,560 options to employees, directors and consultants, at exercise prices ranging from $9.375 to $18.75.

The Incentive Plan supersedes all of the Company’s previous stock option plans, which include the 2004 Stock Option Plan, the 2005 Stock Option Plan and the 2009 Stock Option plan under which the Company had options to purchase 19,052, 42,952 and 142,735 shares of common stock outstanding. The terms and conditions of the options outstanding under these plans remain unchanged. As of July 31, 2013, the Company had total outstanding options of 467,923.

Total compensation cost for the Company’s stock plans recognized in the statement of operations for the three months ended July 31, 2013 was approximately $320,000, of which approximately $98,000 was included in research and development expenses and approximately $222,000 was included in general and administrative expenses. For the three months ended July 31, 2012, total compensation cost for the Company’s stock plans recognized in the statement of operations was approximately $290,000 of which approximately $128,000 was included in research and development expenses and approximately $162,000 was included in general and administrative expenses. For the nine months ended July 31, 2013, total compensation cost for the Company’s stock plans recognized in the statement of operations was approximately $2.6 million of which approximately $1.0 million was included in research and development and approximately $1.6 million was included in general and administrative expenses. For the nine months ended July 31, 2012, total compensation cost for the Company’s stock plans recognized in the statement of operations was approximately $878,000 of which approximately $398,000 was included in research and development and approximately $480,000 was included in general and administrative expenses

The fair value of options granted for the nine months ended July 31, 2013 and 2012 amounted to $1,657,500 and $2,539,792, respectively.

As of July 31, 2013, there was approximately $1,472,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining average vesting period of 1.42 years.

A summary of changes in the stock option plan for nine months ended July 31, 2013 is as follows:

	Number of		Weighted-Average
	Options		Exercise Price
Outstanding at October 31, 2012:		358,459	$	20.00
Granted		134,600	$	9.375
Exercised		-		—
Expired		(25,136)		18.75
Outstanding at July 31, 2013		467,923	$	17.50
Vested and Exercisable at July 31, 2013		290,300	$	17.50

2011 Employee Stock Purchase Plan

The Company’s board of directors adopted the Advaxis, Inc. 2011 Employee Stock Purchase Plan, which it refers to as the ESPP, on August 22, 2011, and its stockholders approved the ESPP on September 27, 2011. The ESPP allows employees to purchase common stock of the Company at an 85% discount to the market price on designated exercise dates. Employees were eligible to participate in the ESPP beginning December 30, 2011 and the Company has reserved40,000 shares of its common stock for issuance under the ESPP.

During the nine months ended July 31, 2013, approximately $22,575 was withheld from employees, on an after-tax basis, in order to purchase approximately 5,290 shares of common stock in February, May and August 2013. During the nine months ended July, 2012, approximately $18,300 was withheld from employees, on an after-tax basis, in order to purchase 1,657 shares of common stock.

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Jul. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	11. COMMITMENTS AND CONTINGENCIES Brio Claim On March 22, 2013, the Company was notified that a lawsuit against it had been filed by Brio Capital L.P., which it refers to as Brio, in the Supreme Court of the State of New York, County of New York, titled Brio Capital L.P. v. Advaxis Inc. , Case No. 651029/2013, which it refers to as the Action. The complaint in the Action alleges, among other things, that the Company breached the terms of certain warrants to purchase shares of its common stock that it originally issued to Brio on October 17, 2007 and on June 18, 2009, each at an initial exercise price of $25.00 per share, and that Brio has suffered damages as a result thereof. Brio’s complaint seeks (i) a preliminary and permanent injunction directing the Company to issue to Brio 21,742 shares of its common stock, along with the necessary corporate resolutions and legal opinions to enable Brio to sell such common stock publicly without restriction; and (ii) damages of at least $500,000 (in an amount to be determined at trial), along with interest, costs and attorneys’ fees related to the Action. On April 15, 2013, in partial settlement of the Brio lawsuit, the Company issued 21,742 shares of common stock, recorded non-cash expense of approximately $232,000 for the nine months ended July 31, 2013 and provided certain corporate resolutions and legal opinions necessary to enable Brio Capital L.P. to sell such common stock publicly without restriction. The Company believes the remaining claims under the Action are entirely without merit, and it intends to vigorously defend itself against the Action. University of Pennsylvania On May 10, 2010, the Company entered into a second amendment to the Penn license agreement pursuant to which it acquired exclusive licenses for an additional 27 patent applications related to its proprietary Listeria vaccine technology. As part of this amendment the Company exercised its option for the rights to seven additional patent dockets, including 23 additional patent applications, at an option exercise fee payable in the form of $35,000 in cash and $70,000 in its common stock (approximately 3,111 shares of its common stock based on a price of $22.50 per share) and agreed to pay historical patent costs incurred by Penn at a cost of approximately $462,000. As of July 31, 2013, the Company owed Penn approximately $460,000 under all licensing agreements. Numoda On June 19, 2009 the Company entered into a Master Agreement and on July 8, 2009 it entered into a Project Agreement with Numoda Corporation, which it refers to as Numoda, a leading clinical trial and logistics management company, to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervical cancer and CIN. Numoda is responsible globally for integrating oversight and logistical functions with the clinical research organizations, contract laboratories, academic laboratories and statistical groups involved. The scope of this agreement covers over three years and is estimated to cost approximately $12.2 million for both trials. Pursuant to the Master Agreement, the Company is permitted to pay a portion of outstanding charges to Numoda in the form of the Company’s common stock and during May 2010, the Company issued 28,000 shares of its common stock to an affiliate of Numoda in satisfaction of $350,000 in services rendered by Numoda to the Company under the Master Agreement. The Company has recorded deferred expenses on the balance sheet for this amount and amortizes this amount to expense over the life of the agreement. As the Company is billed by Numoda on a monthly basis, these costs are capitalized to deferred expenses. As the clinical trials progress in terms of patient enrollment and time, the Company reduces the deferred expense balance and recognizes clinical trials expense on the statement of operations. From inception through July 31, 2013, the Company has paid Numoda approximately $7.65 million. As of July 31, 2013, the Company owed Numoda approximately $1.4 million, which is recorded in Accounts Payable. Numoda- Socius Stock Issuance On July 24, 2012, the Circuit Court of the 11th Judicial Circuit in and for Miami-Dade County, Florida entered an Order Approving Stipulation for Settlement of Claim, which the Company refers to as the Order, in the matter titled Socius CG II, Ltd. v. Advaxis, Inc. The Order, together with the Stipulation for Settlement Claim, which the Company refers to as the Stipulation, provide for the full and final settlement of Socius’s $2,888,860 claim against the Company ($1.8 million claim from Numoda plus approximately $1 million in transaction related costs) in connection with past due invoices relating to clinical trial services, which the Company refers to as the Claim. Socius purchased approximately $1.8 million of the Claim against the Company from Numoda Corporation. Pursuant to the terms of the Order and the Stipulation, the Company issued and delivered to Socius an aggregate of 197,449 shares of its common stock for the entire Claim in the period from July to November 2012, which were subject to adjustment as described in the Stipulation. During the three and nine months ended July 31, 2013, the Company recorded non-cash income of approximately $0 and $615,000 related to the issuance of stock to Socius in settlement of the Claim. Separation Agreement On March 6, 2013, the Company announced the departure of Dr. John Rothman, the Company’s former Executive Vice President of Clinical and Scientific Operations, effective March 1, 2013. On March 20, 2013, the Company entered into a Separation Agreement and General Release with Dr. Rothman, pursuant to which Dr. Rothman released the Company from all claims and agreed to continue to assist the Company as a consultant until February 28, 2014 in exchange for (i) being compensated on an hourly basis for certain project assignments as requested by the Company, (ii) receiving an aggregate of approximately $275,000, paid in installments over the course of the one year consulting period, and (iii) all of the options to purchase shares of the Company’s common stock held by Dr. Rothman being fully vested with the exercise period of such options being extended until March 1, 2015. Office & Laboratory Lease In April 2011, the Company entered into a Sublease Agreement and relocated the current offices and laboratory to an approximately 10,000 square foot leased facility in Princeton, NJ which approximates $21,000 per month plus utilities. Utility costs are estimated to be approximately $7,200 per month and are capped at approximately $10,700 per month. The Company made an initial payment of approximately $54,000 prior to entering the new facility. Approximately $38,000 of the initial $54,000 payment was for the security deposit and was recorded on the balance sheet as a long-term asset. The Sublease Agreement has a termination date of November 29, 2015. The Company expects its annual lease costs to approximate $337,000 per year (approximately $1.02 million in the aggregate) until the termination of this agreement in November 2015. On March 13, 2013, the Company entered into a modification of the Sublease Agreement whereby all unpaid accrued lease amounts and future lease amounts through June 30, 2013, which the Company estimated to be approximately $450,000, would be satisfied by a payment in total of $200,000, with $100,000 paid on March 13, 2013 and $100,000 payable upon the consummation of a future capital raising transaction by the Company. In addition, lease payments for the period July 1, 2013 through November 30, 2015 will be reduced to a total of $20,000 per month. Other Pursuant to a Clinical Research Service Agreement, executed in April 2005, the Company is obligated to pay Pharm–Olam International for service fees related to a Phase I clinical trial. As of July 31, 2013, the Company has no outstanding balance of on this agreement. During the nine months ended July 31, 2013, the Company settled an aged payable balance in the amount of $223,620 for a payment of $75,000, recording non-cash income of approximately $148,000 on this transaction. Sale of Net Operating Losses (NOLs) The Company may be eligible, from time to time, to receive cash from the sale of its Net Operating Losses under the State of New Jersey NOL Transfer Program. In December 2012, the Company received notification that it will receive a net cash amount of approximately $725,000 from the sale of its state NOLs and research and development tax credits for the periods ended October 31, 2010 and 2011. These proceeds were received in January 2013.

SHAREHOLDERS' EQUITY	9 Months Ended
SHAREHOLDERS' EQUITY	Jul. 31, 2013
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	12. SHAREHOLDERS’ EQUITY Equity Enhancement Program On October 26, 2012, the Company entered into a Common Stock Purchase Agreement, which it refers to as the Hanover Purchase Agreement, with Hanover, which requires Hanover to purchase up to $10.0 million of shares of its common stock over the 24-month term following the effectiveness of the resale registration statement. The purchase price for such shares of common stock will be the higher of (i) the minimum price, which the Company refers to as the Floor Price, set forth in its notice electing to effect such issuance, and (ii) 90% of the arithmetic average of the five lowest closing sale prices of the common stock during the applicable ten trading day pricing period (or, if less, the arithmetic average of all trading days with closing sale prices in excess of the Floor Price), subject to adjustment. Each trading day with a closing sale price less than the Floor Price is excluded from the calculation of the purchase price and automatically reduces the number of trading days in the applicable pricing period. In consideration for Hanover’s execution and delivery of the Hanover Purchase Agreement, in connection with the execution and delivery of the Hanover Purchase Agreement, the Company issued Hanover 28,000 Commitment Fee Shares in November 2012. The Company recognized non-cash expense of approximately $157,000 related to the issuance of the Commitment Fee Shares in the nine months ended July 31, 2013. The Company has also agreed to issue Hanover additional Maintenance Fee Shares of its common stock in the event that no shares of common stock have been purchased or sold pursuant to the Hanover Purchase Agreement during any calendar quarter during the 24 month term per the terms of the Hanover Purchase Agreement. The Hanover Purchase Agreement provides for indemnification of Hanover and its affiliates in the event that the Company breaches any of its representations and warranties under the Hanover Purchase Agreement. In connection with the Hanover Purchase Agreement, on October 26, 2012, the Company entered into a registration rights agreement, which it refers to as the Hanover Registration Rights Agreement, with Hanover, and granted to Hanover certain registration rights related to the Commitment Fee Shares, the Maintenance Fee Shares, and the shares issuable under the Hanover Purchase Agreement. Under the Hanover Registration Rights Agreement, the Company filed with the SEC a registration statement for the purpose of registering the resale of the common stock issued to Hanover. During the three months ended July 31, 2013, the Company sold 3,200 shares of its common stock for proceeds totaling $23,940. During the nine months ended July 31, 2013, the Company sold 348,724 shares of its common stock for proceeds totaling $2,934,624. Stock Purchase Agreements During the nine months ended July 31, 2013, the Company sold 17,658 shares of its common stock, to accredited investors, for proceeds totaling approximately $77,250. Ironridge Settlement On December 20, 2012, the Superior Court of the State of California for the County of Los Angeles Central District entered an Order for Approval of Stipulation for Settlement of Claims, which the Company refers to as the Order, in the matter titled Ironridge Global IV, Ltd. vs. Advaxis, Inc. The Order, together with the Stipulation for Settlement of Claims, which the Company refers to as the Stipulation, dated December 19, 2012, between the Company and Ironridge Global IV, Ltd., which it refers to as Ironridge, provides for full and final settlement of Ironridge’s $692,761 claim against the Company in connection with past due invoices relating to attorney fees, which Ironridge purchased pursuant to a Receivable Purchase Agreement, dated December 14, 2012, which the Company refers to as the Claim. Pursuant to the terms of the Order and the Stipulation, the Company was obligated to issue 267,117 shares of its common stock to settle the $692,761 owed. On December 21, 2012, the Company issued and delivered to Ironridge 360,000 shares of its common stock, par value $0.001 per share. Accordingly, Ironridge returned 92,883 shares of its common stock on January 30, 2013. Series B Preferred Stock Financing On July 19, 2010, the Company entered into a Series B Preferred Stock Purchase Agreement with Optimus (the “Series B Purchase Agreement”), pursuant to which Optimus agreed to purchase, upon the terms and subject to the conditions set forth therein and described below, up to $7.5 million of the Company’s newly authorized, non-convertible, redeemable Series B preferred stock (“Series B Preferred Stock”) at a price of $10,000 per share. Under the terms of the Series B Purchase Agreement, subject to the Company’s ability to maintain an effective registration statement for the Warrant Shares (as defined below), the Company may from time to time until July 19, 2013, present Optimus with a notice to purchase a specified amount of Series B Preferred Stock. Subject to satisfaction of certain closing conditions, Optimus is obligated to purchase such shares of Series B Preferred Stock on the 10th trading day after the date of the notice. The Company will determine, in its sole discretion, the timing and amount of Series B Preferred Stock to be purchased by Optimus, and may sell such shares in multiple tranches. Optimus will not be obligated to purchase the Series B Preferred Stock upon the Company’s notice (i) in the event the average closing sale price of the Company’s common stock during the nine trading days following delivery of such notice falls below 75% of the closing sale price of the Company’s common stock on the trading day prior to the date such notice is delivered to Optimus, or (ii) to the extent such purchase would result in the Company and its affiliates beneficially owning more than 9.99% of the Company’s outstanding common stock. The Series B Preferred Stock is only redeemable at the option of the Company as set forth in the Company’s Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock and not otherwise subject to redemption or repurchase by the Company in any circumstances. Pursuant to the Series B Purchase Agreement, on July 19, 2010, the Company issued to an affiliate of Optimus a three-year warrant to purchase up to 324,000 shares of the Company’s common stock (the “Warrant Shares”), at an initial exercise price of $31.25 per share, subject to adjustment as described below. The warrant consists of and is exercisable in tranches, with a separate tranche being created upon each delivery of a tranche notice under the Series B Purchase Agreement. On each tranche notice date, that portion of the warrant equal to 135% of the tranche amount will vest and become exercisable, and such vested portion may be exercised at any time during the exercise period on or after such tranche notice date. On and after the first tranche notice date and each subsequent tranche notice date, the exercise price of the warrant will be adjusted to the closing sale price of a share of the Company’s common stock on the applicable tranche notice date. The exercise price of the warrant may be paid (at the option of the affiliate of Optimus) in cash or by its issuance of a four-year, full-recourse promissory note, bearing interest at 2% per annum, and secured by a specified portfolio of assets. However, such promissory note is not due or payable at any time that (a) the Company is in default of any preferred stock purchase agreement for Series B Preferred Stock or any warrant issued pursuant thereto, any loan agreement or other material agreement or (b) there are any shares of the Series B Preferred Stock issued or outstanding. In addition, the Company redeemed two hundred twenty-six (226) shares of Series B Preferred Stock held by the Investor for an aggregate redemption price of $3,141,004 consisting of (i) cash in an amount of $76,622 and (ii) cancellation of certain promissory notes issued by an affiliate of the Investor to the Company in the aggregate amount of $3,051,000 and accrued interest of approximately $13,382. This resulted in a net promissory note receivable of $9,998,210 as of October 31, 2011. The Company also recorded $50,402, $149,562 and $485,812 in accrued interest on the promissory notes through the three and nine months ended July 31, 2013 and the twelve months ended October 31, 2012, respectively. The value of the Promissory Note and Interest Receivable was $10,633,584 and $10,484,022 as of July 31, 2013 and October 31, 2012, respectively. The promissory bears interest at 2 % per annum which is credited directly to capital. On April 4, 2011, the Company and Optimus entered into an amendment to the Preferred Stock Purchase Agreement dated July 19, 2010 between the Company and Optimus. Under the amendment, Optimus remains obligated, from time to time until July 19, 2013, to purchase up to an additional 284 shares of non-convertible, redeemable Series B Preferred Stock, $0.001 par value per share at a purchase price of $10,000 per share upon notice from the Company to the Investor, subject to the satisfaction of certain conditions set forth in the Purchase Agreement. This agreement shall automatically terminate on the later of the date that (i) is three years after the Effective Date of the Additional Purchase Agreement and (ii) no Notes remain outstanding (the ‘Termination Date’) In order to satisfy certain conditions set forth in the Preferred Stock Purchase Agreement that would allow the Company to require the Investor to purchase the remaining shares of Series B Preferred Stock under the Preferred Stock Purchase Agreement, the Amendment provides that, among other things, the Company will issue to the Holder a three-year warrant (the “ Additional Warrant ”) to purchase up to an additional 204,480 shares of the Company’s common stock, at an initial exercise price of $18.75 per share, subject to adjustment as described below. The Additional Warrant will become exercisable on the earlier of (i) the date on which a registration statement registering for resale the shares of the Company’s common stock issuable upon exercise of the Additional Warrant (the “Warrant Shares”) becomes effective and (ii) the first date on which such Warrant Shares are eligible for resale without limitation under Rule 144 (assuming a cashless exercise of the Additional Warrant). The Additional Warrant consists of and is exercisable in tranches, with a separate tranche being created upon each delivery of a tranche notice under the Preferred Stock Purchase Agreement. On each tranche notice date, that portion of the Additional Warrant equal to 135% of the tranche amount will vest and become exercisable, and such vested portion may be exercised at any time during the exercise period on or after such tranche notice date. On and after the first tranche notice date and each subsequent tranche notice date, the exercise price of the Additional Warrant will be adjusted to the closing sale price of a share of the Company’s common stock on the applicable tranche notice date. The exercise price of the Additional Warrant may be paid (at the option of the Investor) in cash or by the Investor’s issuance of a four-year, full-recourse promissory note (each, a “Promissory Note ”), bearing interest at 2% per annum, and secured by specified portfolio of assets. However, no Promissory Note will be due or payable at any time that (a) the Company is in default of any preferred stock purchase agreement for Series B Preferred Stock or any warrant issued pursuant thereto, any loan agreement or other material agreement or (b) there are any shares of the Company’s Series B Preferred Stock issued or outstanding. The Additional Warrant also provides for cashless exercise in certain circumstances. If a “Funding Default” (as such term is defined in the Additional Warrant) occurs and the Additional Warrant has not previously been exercised in full, the Company has the right to demand surrender of the Additional Warrant (or any remaining portion thereof) without compensation, and the Additional Warrant will automatically be cancelled. Holders of Series B preferred stock will be entitled to receive dividends, which will accrue in shares of Series B preferred stock on an annual basis at a rate equal to 10% per annum from the issuance date. Accrued dividends will be payable upon redemption of the Series B preferred stock or upon the liquidation, dissolution or winding up of our Company. In the event the Company redeems all or a portion of any shares of the Series B Preferred Stock then held by Optimus, Optimus shall apply, and the Company may offset, the proceeds of any such redemption to pay down the accrued interest and outstanding principal of the Promissory Note from Optimus. As of July 31, 2013, the Series B preferred stock had a liquidation preference of $10,277,570 comprised of $10,000 per share plus the total of the cumulative accrued dividends in the amount of $2,877,570. At October 31, 2012 the Series B preferred stock had a liquidation preference of $9,722,570 comprised of $10,000 per share plus the total of the cumulative accrued dividends in the amount of $2,322,570. During the three and nine months ended July 31, 2013 and 2012 and the period from March 1, 2002 (date of inception) to July 31, 2013, the Company accrued dividends of $185,000, $555,000 and $2,877,570 respectively. On April 4, 2011, the Company and the Holder also entered into an Amended and Restated Security Agreement to ensure that any Promissory Note issued upon exercise of the Additional Warrant will be entitled to the benefits of the security and collateral provisions of the Security Agreement dated as of July 19, 2010. During the nine months ended July 31, 2013 and 2012, the Company did not sell any preferred shares to Optimus. As of both July 31, 2013 and October 31, 2012, the Company continued to have 284 shares of its Series B Preferred Stock available for sale to Optimus at a gross purchase price of $10,000.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

FAIR VALUE

9 Months Ended

Jul. 31, 2013

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

13. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii)knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

⋅ Level 1 — Quoted prices in active markets for identical assets or liabilities

⋅ Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities

⋅ Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities

The following table provides the liabilities carried at fair value measured on a recurring basis as of July 31, 2013:

July 31, 2013	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $5.625 - $21.25 from May 2013 through August 2017	$	-	$	$	736,059	$	736,059

July 31, 2013
Short term Convertible Notes Payable at fair value
May 2012 Notes	$	-	$	$	83,333	$	83,333
Asher Notes –May and July 2013					507,830		507,830
Redwood Management LLC					388,751		388,751
JMJ Financial					995,166		995,166
Short-term convertible Notes Payable at fair value			$		1,975,080	$	1,975,080

October 31, 2012	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $6.625 - $21.25 from October 2012 through August 2017	$	-	$	$	434,136	$	434,136

October 31, 2012
Short term Convertible Notes Payable
May 2012 Notes	$	-	$	$	588,313	$	588,313
Hanover PIPE Notes – September & October 2012					362,791		362,791
Magna Exchange Note					333,086		333,086
Asher Note					150,687		150,687
French, Patton & Paterson Notes					208,664		208,664

Short-term convertible Notes and fair value of Embedded Derivative				$	1,643,541	$	1,643,541

Common stock warrant liability:

	July 31, 2013 (Unaudited)
Beginning balance: October 31, 2012	$	434,136
Issuance of common stock warrants		1,460,867
Reclassification of warrant liability to equity		-
Exercise of warrants		(795,411)
Issuance of additional warrants due to anti-dilution provisions		30,887
Change in fair value		(394,420)

Balance at July 31, 2013	$	736,059

Convertible notes at fair value:

	July 31, 2013
	(Unaudited)
Beginning balance – October 31, 2012		1,643,541
Issuance of notes		1,238,277
Transfer-out		(1,808,454)
Change in Fair Value of notes		901,716
Ending balance – July 31, 2013	$	1,975,080

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Jul. 31, 2013
Subsequent Events [Abstract]
Subsequent Events [Text Block]	14. SUBSEQUENT EVENTS Subsequent events have been evaluated through the date that the financial statements were issued. All appropriate subsequent event disclosures, if any, have been made in the notes to the financial statements. On August 1, 2013, pursuant to a private placement agreement, the Company issued 4,000 shares of common stock to a consultant, upon the execution of this agreement. On August 8, 2013, the remaining May 2012 note-holder converted its remaining $83,333 in principal into 26,371 shares of the Company’s common stock at a conversion rate of $3.16. The May 2012 Notes matured on May 18, 2013. There are no remaining May 2012 Notes outstanding. On August 12, 2013, the Company issued 3,600 shares of common stock for consulting services valued at $15,000. On August 12, 2013, the Company issued 2,330 shares of its common stock to employees under the Employee Stock Purchase Plan (ESPP) for an aggregate purchase price of $7,027. On August 14, 2013, the Company issued 15,723 shares of common stock for consulting services valued at $50,000. JMJ Financial On August 14, 2013, the Company borrowed an additional $100,000 under the JMJ April 2013 convertible promissory note. At this date, the Company has borrowed $625,000 under the JMJ April 2013 Note. JMJ Financial has no obligation to lend the Company the remaining $95,000 of available principal amount under the note and may never do so. The Company has no obligation to pay JMJ Financial any amounts on the unfunded portion of the note and may not prepay any portion of the note without JMJ Financial’s consent. On August 9, 2013 and September 5, 2013, JMJ Financial converted $67,515 and $39,600 in principal and interest, respectively on its April 2013 Note into 51,000 shares of common stock at conversion rates ranging from $1.89 to $2.20. After these conversions, approximately $525,000 in principal remained outstanding under the JMJ April 2013 Note. Tonaquint On August 14, 2013, in lieu of a cash installment payment on the outstanding Tonaquint Note, the Company issued 33,309 shares of common stock. Of the 33,309 shares issued to Tonaquint, 21,843 were issued to satisfy the second installment payment consisting of principal in the amount of $49,444 and interest of $5,810 for a total conversion amount of $55,254. This amount was converted at a conversion price of approximately $2.53. The remaining 11,466 shares were issued related to the installment payment, made by the Company in shares, in July 2013 pursuant to a true-up provision in the convertible promissory note agreement that allows Tonaquint to receive additional shares if the conversion price, used at the time of the installment payment, decreases in a stated period of time following said payment. On August 15, 2013, the Company issued 10,500 shares of its common stock to Hanover Holdings in connection with the settlement of a draw down pursuant to the Hanover Purchase Agreement, at a price of approximately $2.81 per share. The per share price for such shares was established under the terms of the Hanover Purchase Agreement. The Company received total net proceeds of $29,516 in connection with this draw down. On August 20, 2013, in a private placement pursuant to a note purchase agreement, the Company issued an accredited investor a secured convertible promissory note in the aggregate principal amount of $108,000, for a purchase price of $100,000. This note bears interest at a rate of 20% per annum and is convertible into shares of the Company’s common stock at a conversion price equal to the lower of $3.00 or 80% of the volume weighted average price for the five days preceding conversion, with a floor price of $2.50. To secure prompt payment under the note, the Company granted the holder a continuing security interest in all net proceeds it receives up to the aggregate amount of $108,000 plus accrued interest from the sale of its NOLs or research and development tax credits through the New Jersey Economic Development Program. This note matures on February 21, 2014, nine months after its issuance, and may not be converted prior to maturity although the Company may prepay this note at any time. In addition, the Company is required to repay this note within three business days of closing any financing greater than $2,000,000. Resignation of Thomas A. Moore and Appointment of Dan O’Connor as Chief Executive Officer At a meeting of the Company’s Board of Directors held on August 14, 2013, Thomas A. Moore indicated his intent to resign as Chairman of the Board of Directors and President and Chief Executive Officer (“CEO”) effective August 19, 2013 in line with the previously contemplated succession plan. Thomas A. Moore continues to serve on the Board of Directors and is acting as a consultant to the Company pursuant to the terms of a consulting agreement dated August 19, 2013, the terms of which are described below. In light of Mr. Moore’s notification to the Board of his intent to resign as President and CEO and the Board’s succession plan, the Board appointed Daniel J. O’Connor (formerly Executive Vice President), to the position of President and CEO, effective August 19, 2013. Mr. O’Connor’s appointment as President and CEO is the outcome of the succession planning initiatives over the past year by Mr. Moore and the Board of Directors. The Board of Directors also fixed the number of Board members at seven and appointed Mr. O’Connor as a Director to fill the newly created vacancy in accordance with the the Company’s Bylaws, all effective August 19, 2013. Mr. O’Connor will hold office as a Director until the next annual meeting of stockholders of the Company subject to his earlier resignation or removal. Mr. O’Connor has not currently been appointed to any standing committee of the Board of Directors. Dr. James Patton, Chairman of the Audit Committee, was elected to serve as Non- executive Chairman of the Board effective August 19, 2013. Thomas A. Moore Consulting and Severance Agreements On August 19, 2013, the Company entered into a consulting agreement with Mr. Moore, which took effect as of such date. Under the consulting agreement, Mr. Moore will assist the development of the Company’s veterinary program and perform the duties assigned by the CEO, the Chairman of the Board and/or Board of Directors related to strategic planning and business development, or any other matter so delegated. Mr. Moore is required to be able to commit at least 20 hours per week to his consulting duties under the agreement. The consulting agreement provides for an initial term of one year, after which it terminates unless the Company notifies Mr. Moore of its intent to renew prior to the expiration of the initial term, following which it will be renewed upon such terms and conditions as they may mutually agree. If the Company elects to continue beyond the initial term, either Mr. Moore or the Company may terminate, at any time for any reason with or without cause upon 90 days written notice. Pursuant to the terms of the consulting agreement, Mr. Moore is entitled to: (i) annualized compensation of $350,000 (payable monthly, with thefirst payment due September 20, 2013), with 12% per annum interest accruing on payments not made in accordance with the agreed terms; (ii)reimbursement for any COBRA costs, (iii) a one-time $100,000 payment if the Company closes a financing greater than $5,000,000 during the initial term of the agreement (which one-time payment may be increased to $429,076.59 at the Company’s discretion if the financing exceeds $15,000,000), which amounts are to be in repayment of loans extended by Mr. Moore to the Company (iv) be treated as non-employee Director for purposes of attendance fees under the Company’s Director compensation program (but not for purposes of the annual retainer), (v) receive a one-time grant of 30,000 options under the Incentive Plan on or around November 1, 2013, and be considered in “Continuous Service” for purposes of his outstanding option awards under the Incentive Plan (as such term is defined in the Incentive Plan) and (v) reimbursement of reasonable documented travel expenses as contemplated by the consulting agreement. Termination Agreement On August 19, 2013, the Company entered into an agreement with a financial advisor to terminate a July 2012 engagement agreement between the parties, pursuant to which the advisor asserted claims for unpaid fees related to the introduction of investors to the Company and services provided. As consideration for terminating the agreement the Company agreed to pay the advisor approximately $589,000 in monthly installment payments in either cash or shares of the Company’s common stock, and a 3-year warrant to purchase 30,154 shares of the Company’s common stock at an exercise price of $4.90 per share. Additionally, the Company agreed to pay the advisor $150,000 upon the completion of a contemplated public offering of securities. Yenson Co. Ltd. On August 28, 2013, the Company entered into a Securities Purchase Agreement with Yenson Co. Ltd (“Investor”). Investor purchased $100,000 of the Company’s common stock at a purchase price of approximately $2.21per share, resulting in 45,353 shares of its common stock being issued. In addition, the investor received 50% warrant coverage, resulting in the issuance of a warrant to purchase 22,161 shares of the Company’s common stock, at an exercise price of $2.76 per warrant. The warrant expires 3 years from the date of the agreement. JMJ Financial On September 4, 2013, the Company entered into a securities purchase agreement with JMJ Financial pursuant to which it issued JMJ Financial, in a private placement, an $800,000 convertible promissory note and 19,231 restricted shares of its common stock as a $50,000 origination fee for the note. The securities agreement provides that the Company will “true up” JMJ Financial by issuing additional shares of its common stock if JMJ Financial does not receive at least $50,000 of net proceeds from the sale of such shares of common stock when, and if, it disposes of such shares. The face amount of the note reflects an aggregate principal amount of $800,000 for total consideration of $720,000 (or a 10% original issue discount). However, the Company has currently only borrowed $500,000 from JMJ Financial under this convertible promissory note, all of which JMJ Financial paid in cash. JMJ Financial has no obligation to lend the remaining $220,000 of available principal amount under the note and may never do so. The Company has no obligation to pay JMJ Financial any amounts on the unfunded portion of the note and may not prepay any portion of the note without JMJ Financial’s consent. The convertible promissory note matures September 4, 2014 and, in addition to the 10% original issue discount, provides for payment of a one time interest charge of 5% on funded amounts. The convertible promissory note is convertible at any time, in whole or in part, at JMJ Financial’s option into shares of the Company’s common stock at the lesser of $2.65 or 70% of the average of the lowest two closing prices in the 20-day pricing period preceding a conversion. However, at no time will JMJ Financial be entitled to convert any portion of the note to the extent that after such conversion, JMJ Financial (together with its affiliates) would beneficially own more than 4.99% of the Company’s outstanding shares common stock as of such date. The Company agreed to reserve at least 2,000,000 shares of its common stock for conversion of the note. The note also provides for penalties and rescission rights if the Company does not deliver shares of its common stock upon conversion with the require timeframes. The convertible promissory note includes customary event of default provisions, and provides for a default rate of the lesser of 18% or the maximum permitted by law. Upon the occurrence of an event of default, the lender may require the Company to pay in cash the “Mandatory Default Amount,” which is defined in the note to mean the greater of (i) the outstanding principal amount of the note plus all interest, liquidated damages and other amounts owing under the note, divided by the conversion price on the date payment of such amount is demanded or paid in full, whichever is lower, multipled by the volume-weighted-average price, or VWAP, on the date payment of such amount is demanded or paid in full, whichever has a higher VWAP, or (ii) 150% of the outstanding principal amount of the note plus 100% of all interest, liquidated damages and other amounts owing under the note. If the Company completes a public offering of $5,000,000 or more, JMJ Financial has the right, at its election, to require it to repay the note, in whole or in part, in amount equal to 125% of the sum of the funded principal amount being repaid plus all accrued and unpaid interest liquidated damages, fees, and other amounts due on such principal amount.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Polices)

9 Months Ended

Jul. 31, 2013

Accounting Policies [Abstract]

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits.

Earnings Per Share, Policy [Policy Text Block]

Net Loss per Share

	As of July 31,
	2013		2012
Warrants		899,494		917,910
Stock Options		467,923		358,459
Convertible Debt (using the if-converted method)		478,695		92,759
Total		1,846,112		1,369,128

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock Based Compensation

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Derivatives, Embedded Derivatives [Policy Text Block]

Derivative Financial Instruments

Hybrid Financial Instruments [Policy Text Block]

Hybrid Financial Instruments

Debt Discount and Amortization Of Debt Discount [Policy Text Block]

Debt Discount and Amortization of Debt Discount

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

Income Tax, Policy [Policy Text Block]

Income Taxes

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Jul. 31, 2013

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share.

	As of July 31,
	2013		2012
Warrants		899,494		917,910
Stock Options		467,923		358,459
Convertible Debt (using the if-converted method)		478,695		92,759
Total		1,846,112		1,369,128

PROPERTY AND EQUIPMENT (Tables)

9 Months Ended

Jul. 31, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment consists of the following:

	July 31, 2013 (Unaudited)		October 31, 2012
Laboratory equipment	$	284,516	$	287,516
Accumulated depreciation		(223,074)		(209,448)
Net Property and Equipment	$	61,442	$	78,068

INTANGIBLE ASSETS (Tables)

9 Months Ended

Jul. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	July 31, 2013 (Unaudited)		October 31, 2012
License	$	651,992	$	651,992
Patents		2,626,365		2,422,409
Total intangibles		3,278,357		3,074,401
Accumulated amortization		(778,566)		(660,646)
Intangible Assets	$	2,499,791	$	2,413,755

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated amortization expense for the next five years is as follows:

Year ended October 31,
2013, remainder	$	35,000
2014		140,000
2015		140,000
2016		140,000
2017		140,000

SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE (Tables)

9 Months Ended

Jul. 31, 2013

Convertible Notes Payable [Abstract]

Schedule of Debt [Table Text Block]

	July 31/ 2013 (Unaudited)		October 31, 2012
October 2011 Note Financing	$	-	$	58,824
December 2011 Note Financing		-		131,928
May 2012 Note Financing		83,333		588,313
Bridge Notes		62,882		185,758
JMJ Financial		995,166		73,590
Hanover Holdings Note		-		362,791
Magna		-		333,086
Chris French		-		25,950
Asher		507,830		150,687
Yvonne Paterson		-		103,804
James Patton		-		78,909
Redwood Management LLC		388,751		-

Total Convertible Notes		2,037,962		2,093,640

Unamortized discount – Original Issue Discount (OID)		-		(4,541)

Current Portion of Convertible Notes	$	2,037,962	$	2,089,099

COMMON STOCK WARRANT LIABILITY (Tables)

9 Months Ended

Jul. 31, 2013

Warrant Liability [Abstract]

Schedule Of Warrant Liability Disclosure [Table Text Block]

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Exchange Warrants - Nonexercisable	$	18.75		278,329	October 2014	July 2012 Exchanges
Common Stock Purchase Warrant	$	18.75		28,632	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		11,628	October 2014 - October 2015	Oct 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		17,706	May 2015 - January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		13,333	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	15.11-21.25		214,416	December 2013 -April 2015	Bridge Notes
Common Stock Purchase Warrant	$	4.375		1,333	December 2015	Stock Purchase Agreement
Common Stock Purchase Warrant	$	18.75		376	N/A	Vendor & Other
Common Stock Purchase Warrant	$	10.625-18.75		29,883	May 2014 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant		5.625-10.625		13,095	October 2015-August 2017	August – September 2012 Convertible Promissory Notes
Common Stock Purchase Warrant		3.57		86,283	December 2014	Tonaquint Promissory Note
		Subtotal:		695,014
Common Stock Purchase Warrant		TBD (1)		204,480	April 2014	Preferred Stock Agreement (4/04/2011)
		Grand Total		899,494

(1)	During December 2011, the Company unreserved for issuance shares related to the preferred stock warrants. If exercisable, exercise price means an amount per warrant share equal to the closing sale price of a share of common stock on the applicable tranche notice date.

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Exchange Warrants- Nonexercisable	$	18.75		278,329	October 2014	July 2012 Warrant Exchanges
Common Stock Purchase Warrant	$	18.75		28,632	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		11,628	October 2014-October 2015	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		17,706	January 2015-January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		22,222	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	14.95-21.25		198,036	January 2013-April 2015	Bridge Notes
Common Stock Purchase Warrant	$	18.75		376	N/A	Vendor & Other
Common Stock Purchase Warrant	$	18.75		29,883	May 2014 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant		6.625-18.75		11,288	October 2015-August 2017	August – September 2012 Convertible Promissory Notes
		Subtotal:		598,100
Common Stock Purchase Warrant		TBD (1)		204,480	April 2014	Preferred Stock Agreement (4/04/2011)
		Grand Total		802,580

(1)

Schedule Of Fair Value Warrant Liability [Table Text Block]

In fair valuing the warrant liability, at July 31, 2013 and October 31, 2012, the Company used the following inputs in its Black-Scholes Model (BSM Model):

	(Unaudited) July 31, 2013			October 31, 2012

Exercise Price:	$	4.375-21.25		$	6.625-21.25

Stock Price		3.50			5.625

Expected Term:		153-1588 days			81-1736 days

Expected Volatility		93.73%-153.00	%		66.51%-146.78	%

Risk Free Rate:		.08%-.0995	%		0.09-.056	%

STOCK OPTIONS: (Tables)

9 Months Ended

Jul. 31, 2013

Equity [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of changes in the stock option plan for nine months ended July 31, 2013 is as follows:

	Number of		Weighted-Average
	Options		Exercise Price
Outstanding at October 31, 2012:		358,459	$	20.00
Granted		134,600	$	9.375
Exercised		-		—
Expired		(25,136)		18.75
Outstanding at July 31, 2013		467,923	$	17.50
Vested and Exercisable at July 31, 2013		290,300	$	17.50

FAIR VALUE (Tables)

9 Months Ended

Jul. 31, 2013

Common Stock Warrant Liability [Member]

Fair Value [Line Items]

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

The following table provides the liabilities carried at fair value measured on a recurring basis as of July 31, 2013:

July 31, 2013	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $5.625 - $21.25 from May 2013 through August 2017	$	-	$	$	736,059	$	736,059

July 31, 2013
Short term Convertible Notes Payable at fair value
May 2012 Notes	$	-	$	$	83,333	$	83,333
Asher Notes –May and July 2013					507,830		507,830
Redwood Management LLC					388,751		388,751
JMJ Financial					995,166		995,166
Short-term convertible Notes Payable at fair value			$		1,975,080	$	1,975,080

October 31, 2012	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $6.625 - $21.25 from October 2012 through August 2017	$	-	$	$	434,136	$	434,136

October 31, 2012
Short term Convertible Notes Payable
May 2012 Notes	$	-	$	$	588,313	$	588,313
Hanover PIPE Notes – September & October 2012					362,791		362,791
Magna Exchange Note					333,086		333,086
Asher Note					150,687		150,687
French, Patton & Paterson Notes					208,664		208,664

Short-term convertible Notes and fair value of Embedded Derivative				$	1,643,541	$	1,643,541

Fair Value, Instruments Classified In Shareholders' Equity Measured On Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Common stock warrant liability:

	July 31, 2013 (Unaudited)
Beginning balance: October 31, 2012	$	434,136
Issuance of common stock warrants		1,460,867
Reclassification of warrant liability to equity		-
Exercise of warrants		(795,411)
Issuance of additional warrants due to anti-dilution provisions		30,887
Change in fair value		(394,420)

Balance at July 31, 2013	$	736,059

Convertible Note [Member]

Fair Value [Line Items]

Fair Value, Instruments Classified In Shareholders' Equity Measured On Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Convertible notes at fair value:

	July 31, 2013
	(Unaudited)
Beginning balance – October 31, 2012		1,643,541
Issuance of notes		1,238,277
Transfer-out		(1,808,454)
Change in Fair Value of notes		901,716
Ending balance – July 31, 2013	$	1,975,080

NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Textual) - USD ($)	9 Months Ended
	Jul. 31, 2013	Jul. 12, 2013	Mar. 10, 2013	Oct. 31, 2012
Schedule Of Nature Of Operations And Basis Of Presentation [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued	$ 800,000
Stockholders Equity, Reverse Stock Split	1-for-125
Common Stock, Par Or Stated Value Per Share	$ 0.001		$ 0.001	$ 0.001
Common Stock, Shares Authorized	25,000,000			25,000,000
Preferred Stock, Shares Authorized	5,000,000			5,000,000
Sale Of Warrant Minimum Price Per Warrant	$ 15.11
Minimum [Member]
Schedule Of Nature Of Operations And Basis Of Presentation [Line Items]
Sale Of Stock, Price Per Share	$ 3.16
Post Reverse Stock Split [Member]
Schedule Of Nature Of Operations And Basis Of Presentation [Line Items]
Common Stock, Par Or Stated Value Per Share		$ 0.001
Capital Units, Authorized		30,000,000
Common Stock, Shares Authorized		25,000,000
Preferred Stock, Shares Authorized		5,000,000

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares	9 Months Ended
	Jul. 31, 2013	Jul. 31, 2012
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Total	1,846,112	1,369,128
Warrant [Member]
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Total	899,494	917,910
Employee Stock Option [Member]
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Total	467,923	358,459
Convertible Debt Securities [Member]
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Total	478,695	92,759

PROPERTY AND EQUIPMENT (Details) - USD ($)	Jul. 31, 2013	Oct. 31, 2012
Property And Equipment [Line Items]
Laboratory equipment	$ 284,516	$ 287,516
Accumulated depreciation	(223,074)	(209,448)
Net Property and Equipment	$ 61,442	$ 78,068

PROPERTY AND EQUIPMENT (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		137 Months Ended
PROPERTY AND EQUIPMENT (Details Textual) - USD ($)	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013
Property And Equipment [Line Items]
Depreciation expense	$ 4,442	$ 4,592	$ 13,626	$ 9,184	$ 223,074

INTANGIBLE ASSETS (Details) - USD ($)	Jul. 31, 2013	Oct. 31, 2012
Finite-Lived Intangible Assets [Line Items]
License	$ 651,992	$ 651,992
Patents	2,626,365	2,422,409
Total intangibles	3,278,357	3,074,401
Accumulated amortization	(778,566)	(660,646)
Intangible Assets	$ 2,499,791	$ 2,413,755

INTANGIBLE ASSETS (Details 1)	Oct. 31, 2012 USD ($)
Amortization Expense Per Equivalent Unit of Production or Per Dollar of Gross Revenue [Line Items]
2013, remainder	$ 35,000
2014	140,000
2015	140,000
2016	140,000
2017	$ 140,000

INTANGIBLE ASSETS (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		137 Months Ended
INTANGIBLE ASSETS (Details Textual) - USD ($)	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Amortization expense of intangibles	$ 40,109	$ 37,435	$ 117,920	$ 109,859	$ 860,562
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Patents Expirations			2014
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Patents Expirations			2023

SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE (Details) - USD ($)	Jul. 31, 2013	Jan. 31, 2013	Oct. 31, 2012
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	$ 2,037,962		$ 2,093,640
Unamortized discount - Original Issue Discount (OID)	0		(4,541)
Current Portion of Convertible Notes	2,037,962		2,089,099
October 2011 Note Financing [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	0		58,824
December 2011 Note Financing [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	0		131,928
Unamortized discount - Original Issue Discount (OID)		$ (26,896)	(26,896)
May 2012 Note Financing [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	83,333		588,313
Bridge Notes [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	62,882		185,758
Jmj Financial [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	995,166		73,590
Hanover Holdings Note [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	0		362,791
Magna [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	0		333,086
Chris French [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	0		25,950
Asher [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	507,830		150,687
Yvonne Paterson [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	0		103,804
James Patton [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	0		78,909
Redwood Management LLC [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	$ 388,751		$ 0

SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE (Details Textual) - USD ($)									1 Months Ended											3 Months Ended	9 Months Ended		12 Months Ended	137 Months Ended
	Aug. 08, 2013	Jul. 12, 2013	Mar. 14, 2013	Dec. 06, 2012	Nov. 12, 2012	Sep. 11, 2012	Aug. 02, 2012	May 14, 2012	Sep. 30, 2013	Jul. 31, 2013	Jun. 27, 2013	Jun. 21, 2013	May 31, 2013	Apr. 26, 2013	Dec. 28, 2012	Oct. 19, 2012	Sep. 19, 2012	Aug. 27, 2012	Jul. 21, 2012	Jul. 31, 2013	Jul. 31, 2013	Jul. 31, 2012	Oct. 31, 2012	Jul. 31, 2013	Aug. 14, 2013	Mar. 10, 2013	Jan. 31, 2013	Dec. 31, 2012
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price																												$ 3.75
Debt Instrument, Maturity Date																			Dec. 31, 2012
Debt Conversion, Converted Instrument, Shares Issued			170,624
Issuance of notes										$ 76,491									$ 250,000	$ 76,491	$ 76,491			$ 76,491
Warrants To Purchase Of Common Stock																					86,283
Long-term Debt, Gross																			$ 250,000							$ 250,000
Original Issue Discount, net of accreted interest										0										0	$ 0		$ 4,541	0
Debt Instrument, Interest Rate, Stated Percentage																			33.00%
Proceeds From Convertible Debt																					2,110,500	$ 500,000		19,969,900
Convertible Notes Payable										2,037,962										2,037,962	2,037,962		2,093,640	2,037,962
Minimum [Member] \| Subsequent Event [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price																									$ 1.89
Maximum [Member] \| Subsequent Event [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price																									$ 2.20
October 2011 Note Financing [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current																							58,824
Debt Conversion, Converted Instrument, Amount																					$ 58,824
Debt Conversion, Converted Instrument, Shares Issued																					18,224
Other Noncash Expense																					$ 70,000
Convertible Notes Payable										$ 0										$ 0	$ 0		58,824	$ 0
October 2011 Note Financing [Member] \| Minimum [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price										$ 3.16										$ 3.16	$ 3.16			$ 3.16
October 2011 Note Financing [Member] \| Maximum [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price										3.25										3.25	3.25			3.25
December 2011 Note Financing [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price										$ 3.49										$ 3.49	$ 3.49			$ 3.49
Debt Conversion, Converted Instrument, Amount																					$ 170,589
Debt Conversion, Converted Instrument, Shares Issued																					48,888
Other Noncash Expense																					$ 104,000
Issuance of notes																							158,824
Original Issue Discount, net of accreted interest																							26,896				$ 26,896
Convertible Notes Payable										$ 0										$ 0	$ 0		131,928	$ 0
May 2012 Note Financing [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current								$ 953,333
Debt Instrument Discount Percentage								25.00%
Debt Instrument, Convertible, Conversion Price								$ 18.75		$ 3.16										$ 3.16	$ 3.16			$ 3.16
Percentage Of Common Stock Issuable Upon Conversion								50.00%
Debt Instrument, Maturity Date								May 18, 2013													May 18, 2012
Debt Conversion, Converted Instrument, Amount																					$ 870,000
Debt Conversion, Converted Instrument, Shares Issued																					275,240
Other Noncash Expense																					$ 25,200
Other Noncash Income																				$ 65,294
Fair Value Of Interest and Additional Warrants Issued								$ 291,400
Exchange Agreement Warrants Excercise Price								$ 18.75
Debt Instrument, Fair Value Disclosure								$ 454,680
Interest and Debt Expense								291,400
Unrealized Gain On Note								266,332
Warrant Liability										$ 18,426										18,426	18,426		112,487	$ 18,426
Convertible Debt										83,000										83,000	83,000			83,000
Proceeds From Convertible Debt								$ 715,000
Convertible Notes Payable										$ 83,333										$ 83,333	$ 83,333		588,313	$ 83,333
May 2012 Note Financing [Member] \| Subsequent Event [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 3.16									$ 3.16										$ 3.16	$ 3.16			$ 3.16
Debt Conversion, Converted Instrument, Amount	$ 83,333																				$ 83,333
Debt Conversion, Converted Instrument, Shares Issued	26,371
Junior Convertible Subordinated Convertible Notes [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current										$ 170,589										$ 170,589	$ 170,589		$ 186,000	$ 170,589
Percentage Of Common Stock Issuable Upon Conversion										6.00%										6.00%	6.00%			6.00%
Debt Conversion, Converted Instrument, Amount																				$ 11,765	$ 11,765
Issuance of notes										$ 158,824										158,824	158,824			$ 158,824
Long-term Debt, Gross										63,000										63,000	63,000			63,000
Minimum Percentage Of Warrant Received Coverage																							23.00%
Maximum Percentage Of Warrant Received Coverage																							75.00%
Exchange Agreement Warrants Excercise Price																							$ 18.75
Jmj Financial [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current															$ 100,000			$ 100,000
Debt Instrument Discount Percentage														10.00%
Debt Instrument, Maturity Date														Apr. 26, 2014
Debt Conversion, Converted Instrument, Amount																					$ 100,000
Debt Conversion, Converted Instrument, Shares Issued																					24,744
Other Noncash Income																					$ 96,000
Long-term Debt, Gross															115,000
Debt Instrument, Fair Value Disclosure										995,166					125,000			73,590		995,166	$ 995,166			995,166
Debt Instrument, Convertible, Terms of Conversion Feature														The convertible promissory note is convertible at any time, in whole or in part, at JMJ Financials option into shares of the Companys common stock at the lesser of $8.75 or 70% of the average of the lowest two closing prices in the 20-day pricing period preceding a conversion.
Common Stock, Capital Shares Reserved for Future Issuance														160,000
Percentage Of Funded Amount Granted To Participate In Public Offering														125.00%
Amount Of Public Offering Require To Pay Note														$ 10,000,000
Proceeds From Convertible Debt														425,000	$ 100,000			$ 100,000
Debt Instrument, Interest Rate Terms																					18
Debt Instrument, Debt Default, Description of Notice of Default																					150% of the outstanding principal amount of the note plus 100% of all interest, liquidated damages and other amounts owing under the note.
Convertible Notes Payable										995,166										995,166	$ 995,166		$ 73,590	995,166
Jmj Financial [Member] \| Private Placement [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current														$ 800,000
Debt Instrument Discount Percentage														10.00%
Debt Conversion Convertible Instrument Remaining Borrowed Amount											$ 195,000
Proceeds From Conversion Of Convertible Debt, Current														$ 300,000
Debt Conversion, Converted Instrument, Amount														125,000
Proceeds From Convertible Debt											$ 100,000			$ 720,000
Jmj Financial [Member] \| Subsequent Event [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Stock Issued During Period, Value, New Issues									$ 5,000,000
Magna [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current										$ 58,824										$ 58,824	58,824			$ 58,824
Debt Conversion, Converted Instrument, Amount																					$ 300,000
Debt Conversion, Converted Instrument, Shares Issued																					80,992
Other Noncash Expense																					$ 44,000
Debt Instrument, Interest Rate, Stated Percentage										6.00%										6.00%	6.00%			6.00%
Debt Instrument, Fair Value Disclosure																							333,086
Convertible Notes Payable										$ 0										$ 0	$ 0		333,086	$ 0
Magna [Member] \| Minimum [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price										$ 3.21										$ 3.21	$ 3.21			$ 3.21
Magna [Member] \| Maximum [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price										4.14										4.14	4.14			4.14
Asher [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current					$ 153,500	$ 103,500
Debt Instrument, Convertible, Conversion Price										$ 6.50										$ 6.50	$ 6.50			$ 6.50
Investors Minimum Beneficially Ownership Percentage					4.99%	4.99%
Debt Conversion, Converted Instrument, Amount																					$ 103,500
Debt Conversion, Converted Instrument, Shares Issued																					16,439
Other Noncash Expense																							47,187
Debt Instrument, Interest Rate, Stated Percentage					8.00%	8.00%
Proceeds From Convertible Debt					$ 150,000	$ 100,000
Percentage Of Volume Arithmetic Average Price					65.00%	61.00%
Convertible Notes Payable										$ 507,830										$ 507,830	$ 507,830		150,687	$ 507,830
Hanover Holdings Notes [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current																	$ 132,500
Debt Instrument, Convertible, Conversion Price										$ 3.75										$ 3.75	$ 3.75			$ 3.75
Debt Conversion, Converted Instrument, Amount																					$ 365,000
Debt Conversion, Converted Instrument, Shares Issued																					97,333
Original Issue Discount, net of accreted interest										$ 72,000										$ 72,000	$ 72,000			$ 72,000
Proceeds From Convertible Debt																	$ 132,500
Hanover Holdings Notes [Member] \| Private Placement [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current				$ 100,000												$ 132,500
Debt Instrument, Convertible, Conversion Price				$ 3.75
Percentage Of Common Stock Issuable Upon Conversion				4.99%
Long-term Debt, Gross										122,092										122,092	122,092			122,092
Debt Instrument, Interest Rate, Stated Percentage				12.00%
Accretion of Discount																				10,055	122,092
Proceeds From Convertible Debt				$ 100,000												$ 132,500
Second Asher Note [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current										$ 153,500										$ 153,500	153,500			$ 153,500
Debt Instrument, Maturity Date										Aug. 14, 2013
Debt Conversion, Converted Instrument, Shares Issued																				44,161
Other Noncash Income																					$ 63,980
Second Asher Note [Member] \| Minimum [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price										$ 3.43										$ 3.43	$ 3.43			$ 3.43
Second Asher Note [Member] \| Maximum [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price										$ 3.90										$ 3.90	$ 3.90			$ 3.90
Chris French [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current										$ 25,000										$ 25,000	$ 25,000			$ 25,000
Debt Instrument, Convertible, Conversion Price										$ 5.625										$ 5.625	$ 5.625			$ 5.625
Debt Instrument, Maturity Date																					Oct. 26, 2015
Debt Conversion, Converted Instrument, Shares Issued																					4,527
Other Noncash Expense																					$ 21,000
Number Of Shares Reserve For Issuance Up On Excise Of Warrants										2,263										2,263	2,263			2,263
Interest Payable, Current										$ 633										$ 633	$ 633			$ 633
Convertible Notes Payable										0										0	0		25,950	0
Yvonne Paterson [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current										$ 100,000										$ 100,000	$ 100,000			$ 100,000
Debt Instrument, Convertible, Conversion Price										$ 5.625										$ 5.625	$ 5.625			$ 5.625
Debt Conversion, Converted Instrument, Shares Issued																					18,107
Other Noncash Expense																					$ 32,000
Warrants To Purchase Of Common Stock																					9,054
Interest Payable, Current										$ 2,532										$ 2,532	$ 2,532			$ 2,532
Convertible Notes Payable										0										0	0		103,804	0
James Patton [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current							$ 66,667			$ 66,667										$ 66,667	$ 66,667			$ 66,667
Debt Instrument Discount Percentage							25.00%
Debt Instrument, Payment Terms							0.75 for each $1.00
Debt Instrument, Convertible, Conversion Price							$ 3.16			$ 3.16										$ 3.16	$ 3.16			$ 3.16
Percentage Of Common Stock Issuable Upon Conversion							50.00%
Investors Minimum Beneficially Ownership Percentage							4.99%
Debt Conversion, Converted Instrument, Shares Issued																				21,092
Other Noncash Expense																					$ 5,700
Other Noncash Income																				$ 8,400
Debt Instrument, Fair Value Disclosure										$ 2,304										2,304	2,304			$ 2,304
Unrealized Gain On Note																				$ 94,000
Unrealized Loss On Note																					$ 3,590
Proceeds From Convertible Debt							$ 50,000
Number Of Shares Reserve For Issuance Up On Excise Of Warrants										1,778										1,778	1,778			1,778
Interest Payable, Current										$ 3,355										$ 3,355	$ 3,355			$ 3,355
Convertible Notes Payable										$ 0										$ 0	$ 0		78,909	$ 0
Third Magna Exchange Note [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price										$ 3.25										$ 3.25	$ 3.25			$ 3.25
Debt Conversion, Converted Instrument, Amount																				$ 111,111	$ 111,111
Debt Conversion, Converted Instrument, Shares Issued																				34,241	34,241
Other Noncash Expense																				$ 106,000	$ 106,000
Third Asher Note [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Other Noncash Expense																					131,462
Debt Instrument, Fair Value Disclosure										$ 334,962										334,962	334,962			$ 334,962
Third Asher Note [Member] \| Private Placement [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current													$ 203,500
Debt Instrument, Maturity Date													Feb. 03, 2014
Investors Minimum Beneficially Ownership Percentage													4.99%
Debt Instrument, Interest Rate, Stated Percentage													8.00%
Proceeds From Convertible Debt													$ 200,000
Percentage Of Volume Arithmetic Average Price													65.00%
Fourth Asher Note [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current		$ 103,500
Investors Minimum Beneficially Ownership Percentage		4.99%
Other Noncash Expense																					69,368
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Debt Instrument, Fair Value Disclosure		$ 172,868
Proceeds From Convertible Debt		$ 100,000
Percentage Of Volume Arithmetic Average Price		65.00%
Fourth Asher Note [Member] \| Private Placement [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Maturity Date		Apr. 16, 2014
Redwood Management LLC [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current												$ 277,777
Debt Instrument Discount Percentage												10.00%
Debt Instrument, Convertible, Conversion Price												$ 6.25
Debt Instrument, Maturity Date												Dec. 30, 2013
Investors Minimum Beneficially Ownership Percentage												4.99%
Other Noncash Expense																					110,972
Debt Instrument, Interest Rate, Stated Percentage												5.00%
Debt Instrument, Fair Value Disclosure										388,751										388,751	$ 388,751			388,751
Debt Instrument, Convertible, Terms of Conversion Feature																					The Company agreed to reserve at least 2.5 times the number of shares of its common stock actually issuable upon full conversion of the Redwood Note, and not to take certain actions without Redwoods consent and granted Redwood the right, at its election, to participate in future financings subject to certain limited exceptions. So long as the Company is not in default, and provided it has given 20 days prior written notice, it may prepay the Redwood Note in full at any time at a premium of 110% of the amount owed (which multiple increases 4 months after the issuance date). In addition, if the Company completes a financing of $7,000,000 or more, Redwood has the right, at its election, to require the Company to repay the Redwood Note in full on the closing date of such financing on the same payment terms as noted in the preceding sentence. The Redwood Note includes customary event of default provisions, and provide for a default rate of 14%.
Proceeds From Convertible Debt												$ 250,000
Percentage Of Volume Weighted Average Price												70.00%
Convertible Notes Payable										$ 388,751										$ 388,751	$ 388,751		$ 0	$ 388,751

NOTES PAYABLE- FORMER OFFICER: (Details Textual) - USD ($)	3 Months Ended	9 Months Ended	137 Months Ended
	Jul. 31, 2013	Jul. 31, 2013	Jul. 31, 2013	Mar. 10, 2013	Oct. 31, 2012	Jul. 21, 2012
Schedule Of Notes Payable officer [Line Items]
Long-term Debt, Gross				$ 250,000		$ 250,000
Common Stock, Value, Issued	$ 4,898	$ 4,898	$ 4,898		$ 3,158
Moore Notes [Member]
Schedule Of Notes Payable officer [Line Items]
Debt Instrument, Interest Rate During Period		12.00%
Repayments of Debt		$ 85,700
Long-term Debt, Gross	428,000	428,000	428,000		$ 477,000
Interest Expense, Debt	7,198	24,841	324,862
Notes Payable, Current	11,200	11,200	11,200
Common Stock, Value, Issued	$ 6,000,000	$ 6,000,000	$ 6,000,000
Debt Instrument, Description		In August 2013, Mr. Moore resigned as Chairman of the Board of Directors and as Chief Executive Officer and entered into a consulting agreement with the Company, which provided for a $100,000 payment towards the Moore Notes in the event the Company closes a financing greater than $5,000,00 during the initial term of the consulting agreement (which amount may be increased to $429,076.59 at the Company’s discretion if the financing exceeds $15,000,000).

NOTES PAYABLE-OTHER: (Details Textual) - USD ($)		1 Months Ended
NOTES PAYABLE-OTHER: (Details Textual) - USD ($)	Mar. 10, 2013	Jul. 21, 2012	Jul. 31, 2013	Dec. 31, 2012	Oct. 31, 2012
Schedule Of Notes Payable other [Line Items]
Interest Related To Promissory Note	$ 37,000	$ 37,000
Long-term Debt, Gross	$ 250,000	$ 250,000
Debt Instrument, Interest Rate, Stated Percentage		33.00%
Debt Instrument, Maturity Date		Dec. 31, 2012
Issuance of notes		$ 250,000	$ 76,491
Common stock, par value (in dollars per share)	$ 0.001		$ 0.001		$ 0.001
Debt Instrument, Convertible, Conversion Price				$ 3.75

LONG-TERM CONVERTIBLE NOTE (Details Textual) - USD ($)		3 Months Ended	9 Months Ended
LONG-TERM CONVERTIBLE NOTE (Details Textual) - USD ($)	Mar. 14, 2013	Jul. 31, 2013	Jul. 31, 2013	Mar. 19, 2013	Mar. 13, 2013	Dec. 31, 2012	Dec. 13, 2012	Oct. 31, 2012	Jul. 31, 2012	Jul. 21, 2012	Oct. 31, 2011	Feb. 28, 2002
Schedule Of Long term Convertible Note [Line Items]
Convertible Notes Payable		$ 2,037,962	$ 2,037,962					$ 2,093,640
Debt Instrument, Interest Rate, Stated Percentage										33.00%
Debt Instrument, Convertible, Conversion Price						$ 3.75
Cash		40	40					232	$ 5,288		$ 1,096,538	$ 0
Share Percentage Of Notes Payable To Be Purchased Upon Warrant Issued							75.00%
Long-term Convertible Note (less unamortized debt discount of $66,148)		1,104,680	$ 1,104,680				$ 890,000	$ 0
Debt Instrument, Maturity Period							5 years
Debt Conversion, Converted Instrument, Shares Issued	170,624
Warrants To Purchase Of Common Stock			86,283
Tonaquint Note [Member]
Schedule Of Long term Convertible Note [Line Items]
Convertible Notes Payable		$ 49,444	$ 49,444				$ 890,000
Debt Instrument, Interest Rate, Stated Percentage							8.00%
Debt Instrument, Convertible, Conversion Price		$ 3.57	$ 3.57				$ 20.00
Description On Stock Issued For Installment Payment Of Note			stock will be issued at a price per share equal to 80% of the average of the 5 lowest daily closing bid prices for the common stock during the 20 consecutive trading days prior to the installment date (which is adjusted to 70% if the average of the 3 lowest volume weighted average prices during such 20-day period is less than $1.25 per share)
Long-term Convertible Note (less unamortized debt discount of $66,148)		$ 1,104,680	$ 1,104,680
Debt Conversion, Converted Instrument, Shares Issued		27,583
Secured Long-term Debt, Noncurrent				$ 202,657	$ 202,493
Debt Instrument, Payment Terms			Beginning in June 2013, the Company began making monthly installment payments on the Tonaquint Note as required by the terms of the note, which contemplates 18 installment payments equal to approximately $50,000.
Debt Instrument, Increase, Accrued Interest		$ 49,000
Other Noncash Expense		$ 264,124
Tonaquint Note [Member] \| Second Mortgage [Member]
Schedule Of Long term Convertible Note [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							5.00%
Cash							$ 400,000
Secured Long-term Debt, Noncurrent							$ 200,000

COMMON STOCK WARRANT LIABILITY (Details) - $ / shares

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Class of Warrant or Right [Line Items]

Class of Warrant or Right, Outstanding

899,494

802,580

Maximum [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 21.25

Minimum [Member]

Class of Warrant or Right [Line Items]

Exercise Price

5.625

6.625

Common Stock Purchase Warrant [Member] | July 2012 Warrant Exchanges [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Class of Warrant or Right, Outstanding

278,329

Expiration Date

October 2014

Common Stock Purchase Warrant [Member] | May 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Class of Warrant or Right, Outstanding

28,632

Expiration Date

May 2015

Common Stock Purchase Warrant [Member] | October 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Class of Warrant or Right, Outstanding

11,628

Common Stock Purchase Warrant [Member] | December 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Class of Warrant or Right, Outstanding

17,706

Common Stock Purchase Warrant [Member] | May 2012 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Class of Warrant or Right, Outstanding

13,333

22,222

Expiration Date

May 2017

Common Stock Purchase Warrant [Member] | Bridge Notes [Member]

Class of Warrant or Right [Line Items]

Class of Warrant or Right, Outstanding

214,416

198,036

Common Stock Purchase Warrant [Member] | Vendor and Other [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Class of Warrant or Right, Outstanding

376

Expiration Date

N/A

Common Stock Purchase Warrant [Member] | Placement Agent Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Class of Warrant or Right, Outstanding

29,883

Common Stock Purchase Warrant [Member] | August and September 2012 Convertible Promissory Notes [Member]

Class of Warrant or Right [Line Items]

Class of Warrant or Right, Outstanding

13,095

11,288

Common Stock Purchase Warrant [Member] | Preferred Stock Agreement [Member]

Class of Warrant or Right [Line Items]

Class of Warrant or Right, Outstanding

^[1]

204,480

Expiration Date

^[1]

April 2014

Common Stock Purchase Warrant [Member] | Subtotal [Member]

Class of Warrant or Right [Line Items]

Class of Warrant or Right, Outstanding

695,014

598,100

Common Stock Purchase Warrant [Member] | Tonaquint Promissory Note [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 3.57

Class of Warrant or Right, Outstanding

86,283

Expiration Date

December 2014

Common Stock Purchase Warrant [Member] | Stock Purchase Agreement [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 4.375

Class of Warrant or Right, Outstanding

1,333

Expiration Date

December 2015

Common Stock Purchase Warrant [Member] | Maximum [Member] | October 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Expiration Date

October 2015

Common Stock Purchase Warrant [Member] | Maximum [Member] | December 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Expiration Date

January 2016

Common Stock Purchase Warrant [Member] | Maximum [Member] | Bridge Notes [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 21.25

Expiration Date

April 2015

Common Stock Purchase Warrant [Member] | Maximum [Member] | Placement Agent Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Expiration Date

May 2017

Common Stock Purchase Warrant [Member] | Maximum [Member] | August and September 2012 Convertible Promissory Notes [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 10.625

$ 18.75

Expiration Date

August 2017

Common Stock Purchase Warrant [Member] | Minimum [Member] | October 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Expiration Date

October 2014

Common Stock Purchase Warrant [Member] | Minimum [Member] | December 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Expiration Date

May 2015

January 2015

Common Stock Purchase Warrant [Member] | Minimum [Member] | Bridge Notes [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 15.11

$ 14.95

Expiration Date

December 2013

January 2013

Common Stock Purchase Warrant [Member] | Minimum [Member] | Placement Agent Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 10.625

Expiration Date

May 2014

Common Stock Purchase Warrant [Member] | Minimum [Member] | August and September 2012 Convertible Promissory Notes [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 5.625

$ 6.625

Expiration Date

October 2015

[1]	During December 2011, the Company unreserved for issuance shares related to the preferred stock warrants. If exercisable, exercise price means an amount per warrant share equal to the closing sale price of a share of common stock on the applicable tranche notice date.

COMMON STOCK WARRANT LIABILITY (Details 1) - $ / shares	9 Months Ended	12 Months Ended
COMMON STOCK WARRANT LIABILITY (Details 1) - $ / shares	Jul. 31, 2013	Oct. 31, 2012
Class of Warrant or Right [Line Items]
Stock Price	$ 3.50	$ 5.625
Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price:	$ 4.375	$ 6.625
Expected term: (Days)	153 days	81 days
Expected Volatility %	93.73%	66.51%
Risk Free Rate: %	0.08%	0.09%
Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price:	$ 21.25	$ 21.25
Expected term: (Days)	1588 days	1736 days
Expected Volatility %	153.00%	146.78%
Risk Free Rate: %	0.0995%	0.056%

COMMON STOCK WARRANT LIABILITY (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended	137 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Oct. 31, 2012	Jul. 31, 2013
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	899,494		899,494		802,580	899,494
Proceeds from exercise of warrants			$ 94,444	$ 411,765		$ 1,761,210
Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.625		$ 5.625		$ 6.625	$ 5.625
Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 21.25		$ 21.25		$ 21.25	$ 21.25
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	499,000		499,000			499,000
Exercise of warrants			$ 278,000
Derivative Liability, Fair Value, Gross Liability	$ 736,000		736,000		$ 434,000	$ 736,000
Non Cash Warrant Expenses			$ 1,100,000
Non Cash Warrant Income				$ 4,900,000
Warrants Subject To Anti Dilution Provisions			804,000
Derivative, Gain (Loss) on Derivative, Net, Total	$ 1,800,000	$ 1,700,000
Warrant Liability [Member] \| Common Stock [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	899,000		899,000			899,000
Derivative Liability, Fair Value, Gross Liability					$ 682,000
Warrant Equity [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	122,000		122,000		121,000	122,000
Exercise of warrants			$ 278,329
Warrants With Anti Dilution Provisions [Member]
Class of Warrant or Right [Line Items]
Reduction In Warrant Outstanding Subject To Anti Dilution Provision			$ 124,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 15.11		$ 15.11		$ 18.70	$ 15.11
Warrants Subject To Anti Dilution Provisions			124,000
Anti Dilution Provisions Additional Warrants Issuable	10,000
Anti Dilution Provisions Additional Warrants Exercise Price			$ 25.00		$ 12.50
Warrants With Anti Dilution Provisions [Member] \| Common Stock [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	621,165		621,165			621,165
Warrants With Anti Dilution Provisions [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Probability Of Exercise Of Additional Warrants At Exercise Price One			40.00%
Probability Of Exercise Of Additional Warrants At Exercise Price Two			50.00%
Warrants With Anti Dilution Provisions [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Probability Of Exercise Of Additional Warrants At Exercise Price One			50.00%
Probability Of Exercise Of Additional Warrants At Exercise Price Two			60.00%
Warrant [Member] \| Common Stock [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	899,000		899,000		803,000	899,000
Derivative Liability, Fair Value, Gross Liability	$ 777,000		$ 777,000			$ 777,000
Warrant [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.375		$ 4.375		$ 6.625	$ 4.375
Warrant [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	21.25		$ 21.25		$ 21.25	21.25
Exercise Of Warrants [Member]
Class of Warrant or Right [Line Items]
Exercises Of Warrants			8,889	21,961
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 10.625	$ 18.75	$ 10.625	$ 18.75		$ 10.625
Proceeds from exercise of warrants			$ 94,444	$ 412,000

STOCK OPTIONS: (Details)	9 Months Ended
STOCK OPTIONS: (Details)	Jul. 31, 2013 $ / shares shares
Schedule Of Stock Options [Line Items]
Outstanding Number of Options Beginning Balnce \| shares	358,459
Granted Number of Options \| shares	134,600
Exercised Number of Options \| shares	0
Expired Number of Options \| shares	(25,136)
Outstanding Number of Options Ending Balance \| shares	467,923
Vested and Exercisable Number of Options Ending Balance \| shares	290,300
Outstanding Weighted-Average Exercise Price Beginning Balance \| $ / shares	$ 20.00
Granted Weighted-Average Exercise Price \| $ / shares	9.375
Exercised Weighted-Average Exercise Price \| $ / shares	0
Expired Weighted Average Exercise Price \| $ / shares	18.75
Outstanding Weighted-Average Exercise Price Ending Balance \| $ / shares	17.50
Vested and Exercisable Weighted-Average Exercise Price Ending Balance \| $ / shares	$ 17.50

STOCK OPTIONS: (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		137 Months Ended
STOCK OPTIONS: (Details Textual) - USD ($)	Aug. 22, 2011	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Oct. 31, 2012	Aug. 13, 2012	Sep. 27, 2011
Schedule Of Stock Options [Line Items]
Vested & Exercisable Weighted Average Remaining Contractual Life In Years				1 year 5 months 1 day
Common stock, shares authorized		25,000,000		25,000,000		25,000,000	25,000,000
Granted Weighted-Average Exercise Price				$ 9.375
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		467,923		467,923		467,923	358,459
Non-cash charges to consultants and employees for options and stock				$ 3,103,122	$ 877,251	$ 8,240,668
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value				1,657,500	2,539,792
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options		$ 1,472,000		1,472,000		$ 1,472,000
Employee Stock Ownership Plan (ESOP), Compensation Expense		320,000	$ 290,000	2,600,000	878,000
General and Administrative Expense [Member]
Schedule Of Stock Options [Line Items]
Non-cash charges to consultants and employees for options and stock		222,000	162,000	1,600,000	480,000
Research and Development Expense [Member]
Schedule Of Stock Options [Line Items]
Non-cash charges to consultants and employees for options and stock		$ 98,000	$ 128,000	$ 1,000,000	398,000
Employees and Consultants [Member]
Schedule Of Stock Options [Line Items]
Options granted to consultants and professionals (in shares)				271,560
Employees and Consultants [Member] \| Minimum [Member]
Schedule Of Stock Options [Line Items]
Granted Weighted-Average Exercise Price				$ 9.375
Employees and Consultants [Member] \| Maximum [Member]
Schedule Of Stock Options [Line Items]
Granted Weighted-Average Exercise Price				$ 18.75
Two Thousand and Four Stock Option Plan [Member]
Schedule Of Stock Options [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		19,052		19,052		19,052
Two Thousand and Five Stock Option Plan [Member]
Schedule Of Stock Options [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		42,952		42,952		42,952
Two Thousand and Nine Stock Option Plan [Member]
Schedule Of Stock Options [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		142,735		142,735		142,735
Two Thousand and Eleven Omnibus Incentive Plan [Member]
Schedule Of Stock Options [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance									160,000
Common stock, shares authorized								520,000
Two Thousand and Eleven Employee Stock Purchase Plan [Member]
Schedule Of Stock Options [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	85.00%
Common Stock, Capital Shares Reserved for Future Issuance	40,000
Proceeds from Stock Plans				$ 5,290	1,657
Income Tax Effects Allocated Directly to Equity, Employee Stock Options				$ 22,575	$ 18,300

COMMITMENTS AND CONTINGENCIES (Details Textual)				1 Months Ended				3 Months Ended	9 Months Ended
COMMITMENTS AND CONTINGENCIES (Details Textual)	Mar. 13, 2013 USD ($)	Mar. 06, 2013 USD ($)	May 10, 2010 USD ($) $ / shares shares	Mar. 22, 2013 USD ($) $ / shares shares	Dec. 20, 2012 shares	Apr. 30, 2011 USD ($) ft²	Jul. 31, 2009 USD ($)	Jul. 31, 2013 USD ($) $ / shares shares	Jul. 31, 2013 USD ($) $ / shares shares	Oct. 31, 2012 $ / shares shares	Jul. 24, 2012 USD ($)
Commitments And Contingencies [Line Items]
Stock Price \| $ / shares								$ 3.50	$ 3.50	$ 5.625
Common stock, shares issued \| shares								4,898,248	4,898,248	3,158,433
Non Cash Income								$ 148,000	$ 148,000
Accounts payable								223,620	223,620
Settlement Claim								75,000	75,000
Proceeds From Net Operating Losses									725,000
Area of Land \| ft²						10,000
Common Stock [Member]
Commitments And Contingencies [Line Items]
Stock Issued (in shares) \| shares					267,117
Brio Claim [Member]
Commitments And Contingencies [Line Items]
Stock Price \| $ / shares				$ 25.00
Loss Contingency Damages Sought Shares \| shares				21,742
Loss Contingency, Damages Sought, Value				$ 500,000
Brio Claim [Member] \| Common Stock [Member]
Commitments And Contingencies [Line Items]
Other Noncash Expense									232,000
Separation Agreement [Member]
Commitments And Contingencies [Line Items]
General Release Agreement		$ 275,000
Office and Laboratory Lease [Member]
Commitments And Contingencies [Line Items]
Payments for Leasing Costs						$ 21,000
Cost of Utilities						7,200
Cost Of Utilities Per R E						$ 10,700
Lease Expiration Date						Nov. 29, 2015
Expected Lease Operating Expenses						$ 38,000			337,000
Operating Leases, Rent Expense						$ 54,000			1,020,000
Estimated Utility Cost	$ 450,000
Accelerated Share Repurchases, Settlement (Payment) or Receipt	200,000
Operating Leases, Future Minimum Payments Due, Next Twelve Months	100,000
Operating Leases, Future Minimum Payments, Due in Two Years	100,000
Reduced Monthly Lease Payment Under Sublease Agreement	$ 20,000
Pennsylvania [Member]
Commitments And Contingencies [Line Items]
Option Exercise Fee Payable			$ 35,000
Stock issued			$ 70,000
Stock Issued (in shares) \| shares			3,111
Stock Price \| $ / shares			$ 22.50
Historical Patent Costs			$ 462,000
Licensing Agreement Expenses									460,000
Numoda [Member]
Commitments And Contingencies [Line Items]
Stock issued			$ 350,000
Stock Issued (in shares) \| shares			28,000
Due from Affiliates								7,650,000	7,650,000
Total Projected Agreement Cost							$ 12,200,000
Accounts payable								$ 1,400,000	$ 1,400,000
Numoda Socius Stock Issuance [Member]
Commitments And Contingencies [Line Items]
Common stock, shares issued \| shares								197,449	197,449
Other Noncash Income								$ 0	$ 615,000
Clinical Trail Services Settlement Claim											$ 2,888,860
Settlement Claim											1,800,000
Settlement Claim Towards Transaction Related Costs											$ 1,000,000

SHAREHOLDERS' EQUITY (Details Textual) - USD ($)		1 Months Ended						3 Months Ended		9 Months Ended		12 Months Ended	137 Months Ended
SHAREHOLDERS' EQUITY (Details Textual) - USD ($)	Apr. 04, 2011	Jan. 30, 2013	Dec. 21, 2012	Dec. 20, 2012	Nov. 30, 2012	Oct. 31, 2011	Jul. 19, 2010	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Oct. 31, 2012	Jul. 31, 2013	Mar. 10, 2013	Oct. 26, 2012	Jul. 21, 2012
Shareholders Equity [Line Items]
Preferred stock, shares authorized								5,000,000		5,000,000		5,000,000	5,000,000
Debt Instrument, Interest Rate, Stated Percentage																33.00%
Common stock, par value (in dollars per share)								$ 0.001		$ 0.001		$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Amount of Preferred Dividends in Arrears								$ 185,000	$ 185,000	$ 555,000	$ 555,000		$ 2,877,570
Promissory Note Receivable								$ 10,633,584		10,633,584		$ 10,484,022	10,633,584
Note receivable in connection with exercise of warrants										0	0		9,998,210
Net proceeds of issuance of common stock										$ 3,011,872	$ 0		$ 15,000,102
Preferred Stock, Dividend Rate, Percentage										10.00%
Promissory Note [Member]
Shareholders Equity [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							2.00%	2.00%		2.00%			2.00%
Accrued Interest On Promissory Note								$ 50,402		$ 149,562		$ 485,812
Note receivable in connection with exercise of warrants						$ 9,998,210
Investor [Member] \| Stock Purchase Agreement [Member]
Shareholders Equity [Line Items]
Stock Issued (in shares)										17,658
Net proceeds of issuance of common stock										$ 77,250
Minimum [Member]
Shareholders Equity [Line Items]
Sale of Stock, Price Per Share								$ 3.16		$ 3.16			$ 3.16
Class of Warrant or Right, Exercise Price of Warrants or Rights								5.625		5.625		$ 6.625	5.625
Maximum [Member]
Shareholders Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 21.25		$ 21.25		21.25	21.25
Common Stock [Member]
Shareholders Equity [Line Items]
Stock Issued (in shares)				267,117
Legal Settlement Liability				$ 692,761
Hanover Purchase Agreement [Member]
Shareholders Equity [Line Items]
Closing Sale Price Percentage															90.00%
Purchase Of Shares															10,000,000
Stock Issued (in shares)								3,200		348,724
Other Noncash Expense					$ 28,000					$ 157,000
Net proceeds of issuance of common stock								$ 23,940		$ 2,934,624
Ironridge Settlement [Member]
Shareholders Equity [Line Items]
Stock Issued (in shares)			360,000
Common Stock Shares Returned		92,883
Common stock, par value (in dollars per share)			$ 0.001
Attorney Fees				$ 692,761
Series B Preferred Stock [Member]
Shareholders Equity [Line Items]
Sale of Stock, Price Per Share	$ 10,000						$ 10,000	$ 10,000		$ 10,000		$ 10,000	$ 10,000
Preferred stock, shares authorized							7,500,000
Closing Sale Price Percentage							75.00%
Outstanding Stock Percentage							9.99%
Preferred Stock Shares Available For Sale	284							284		284		284	284
Class Of Options Or Right Number Of Securities Called By Options Or Rights							324,000
Exercise Price Of Options							$ 31.25
Percentage Of Warrant Vest and Exercisable							135.00%
Common stock, par value (in dollars per share)	$ 0.001
Liquidation preference								$ 10,277,570		$ 10,277,570		$ 10,277,570	$ 10,277,570
Preferred Stock, Liquidation Preference Per Share								$ 10,000		$ 10,000		$ 10,000	$ 10,000
Preferred Stock, Amount of Preferred Dividends in Arrears										$ 2,877,570		$ 2,322,570
Preferred Stock redeemed (in shares)							226
Preferred Stock redeemed							$ 3,141,004
Stock Redeemed Or Called During Period Value Paid In Cash							76,622
Stock Redeemed Or Called During Period Value Paid In Extinguishment Of Interest Debt Outstanding							13,382
Stock Redeemed Or Called During Period Value Paid In Extinguishment Of Debt Outstanding							$ 3,051,000
Series B Preferred Stock [Member] \| Warrant [Member]
Shareholders Equity [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.00%
Additional Warrant In Percentage	135.00%
Stock Issued (in shares)	204,480
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 18.75

FAIR VALUE (Details) - USD ($)	Jul. 31, 2013	Oct. 31, 2012
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable	$ 736,059	$ 434,136
May 2012 Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	83,333	588,313
Asher Note [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	507,830	150,687
French, Patton & Paterson Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability		208,664
Jmj Financial [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	995,166
Short Term Convertible Notes and Fair Value Of Embedded Derivative [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	1,975,080	1,643,541
Hanover PIPE Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability		362,791
Magna Exchange Note [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability		333,086
Redwood Management LLC [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	388,751
Fair Value, Inputs, Level 1 [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable	0	0
Fair Value, Inputs, Level 1 [Member] \| May 2012 Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable	736,059	434,136
Fair Value, Inputs, Level 3 [Member] \| May 2012 Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	83,333	588,313
Fair Value, Inputs, Level 3 [Member] \| Asher Note [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	507,830	150,687
Fair Value, Inputs, Level 3 [Member] \| French, Patton & Paterson Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability		208,664
Fair Value, Inputs, Level 3 [Member] \| Jmj Financial [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	995,166
Fair Value, Inputs, Level 3 [Member] \| Short Term Convertible Notes and Fair Value Of Embedded Derivative [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	1,975,080	1,643,541
Fair Value, Inputs, Level 3 [Member] \| Hanover PIPE Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability		362,791
Fair Value, Inputs, Level 3 [Member] \| Magna Exchange Note [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability		$ 333,086
Fair Value, Inputs, Level 3 [Member] \| Redwood Management LLC [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	$ 388,751

FAIR VALUE (Details 1) - Common Stock Warrant Liability [Member]	9 Months Ended
	Jul. 31, 2013 USD ($)
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance - October 31, 2012	$ 434,136
Issuance of common stock warrants	1,460,867
Reclassification of warrant liability to equity	0
Exercise of warrants	(795,411)
Issuance of additional warrants due to anti-dilution provisions	30,887
Change in fair value	(394,420)
Balance at July 31, 2013	$ 736,059

FAIR VALUE (Details 2) - Convertible Notes [Member]	9 Months Ended
FAIR VALUE (Details 2) - Convertible Notes [Member]	Jul. 31, 2013 USD ($)
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance - October 31, 2012	$ 1,643,541
Issuance of notes	1,238,277
Transfer-out	(1,808,454)
Change in Fair Value of notes	901,716
Balance at July 31, 2013	$ 1,975,080

FAIR VALUE (Details Textual) - $ / shares	Jul. 31, 2013	Oct. 31, 2012
Minimum [Member]
Fair Value [Line Items]
Exercise Price	$ 5.625	$ 6.625
Maximum [Member]
Fair Value [Line Items]
Exercise Price	$ 21.25	$ 21.25

SUBSEQUENT EVENTS (Details Textual) - USD ($)										1 Months Ended					9 Months Ended		137 Months Ended
SUBSEQUENT EVENTS (Details Textual) - USD ($)	Sep. 04, 2013	Aug. 15, 2013	Aug. 14, 2013	Aug. 12, 2013	Aug. 08, 2013	Mar. 14, 2013	Nov. 12, 2012	Sep. 11, 2012	May 14, 2012	Aug. 28, 2013	Aug. 20, 2013	Aug. 19, 2013	Jul. 31, 2013	Jul. 21, 2012	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Sep. 05, 2013	Aug. 09, 2013	Mar. 10, 2013	Dec. 31, 2012	Oct. 31, 2012
Subsequent Event [Line Items]
Debt Instrument, Convertible, Conversion Price																					$ 3.75
Debt Instrument, Face Amount													$ 76,491	$ 250,000	$ 76,491		$ 76,491
Stock Price													$ 3.50		$ 3.50		$ 3.50					$ 5.625
Net Proceeds Of Issuance Of Common Stock															$ 3,011,872	$ 0	$ 15,000,102
Debt Instrument, Interest Rate, Stated Percentage														33.00%
Long-term Debt, Gross														$ 250,000						$ 250,000
Proceeds From Convertible Debt															2,110,500	500,000	19,969,900
Proceeds From Notes Payable															0	$ 2,388,963	250,000
Convertible Notes Payable													$ 2,037,962		2,037,962		$ 2,037,962					$ 2,093,640
Debt Conversion, Converted Instrument, Shares Issued						170,624
Debt Instrument, Maturity Date														Dec. 31, 2012
Asher [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Amount															$ 103,500
Debt Instrument, Convertible, Conversion Price													$ 6.50		$ 6.50		$ 6.50
Convertible Notes Payable, Current							$ 153,500	$ 103,500
Debt Instrument, Interest Rate, Stated Percentage							8.00%	8.00%
Proceeds From Convertible Debt							$ 150,000	$ 100,000
Convertible Notes Payable													$ 507,830		$ 507,830		$ 507,830					150,687
Debt Conversion, Converted Instrument, Shares Issued															16,439
Investors Minimum Beneficially Ownership Percentage							4.99%	4.99%
May 2012 Note Financing [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Amount															$ 870,000
Debt Instrument, Convertible, Conversion Price									$ 18.75				$ 3.16		$ 3.16		$ 3.16
Convertible Debt													$ 83,000		$ 83,000		$ 83,000
Convertible Notes Payable, Current									$ 953,333
Proceeds From Convertible Debt									$ 715,000
Convertible Notes Payable													$ 83,333		$ 83,333		$ 83,333					$ 588,313
Debt Conversion, Converted Instrument, Shares Issued															275,240
Debt Instrument Discount Percentage									25.00%
Debt Instrument, Maturity Date									May 18, 2013						May 18, 2012
Termination Agreement [Member]
Subsequent Event [Line Items]
Advisory Fees For Services In Termination Of Agreement												$ 589,000
Class Of Warrant Term Of Warrants												3 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												30,154
Class Of Warrant Exercise Price Of Warrants												$ 4.90
Additional Advisory Fees For Services In Termination Of Agreement												$ 150,000
Minimum [Member]
Subsequent Event [Line Items]
Class Of Warrant Exercise Price Of Warrants													$ 5.625		$ 5.625		$ 5.625					$ 6.625
Maximum [Member]
Subsequent Event [Line Items]
Class Of Warrant Exercise Price Of Warrants													$ 21.25		$ 21.25		21.25					$ 21.25
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues			51,000
Stock Issued During Period, Shares, Issued for Services			15,723	3,600
Stock Issued During Period, Value, Issued for Services			$ 50,000	$ 15,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans				2,330
Stock Issued During Period, Value, Employee Stock Purchase Plan				$ 7,027
Subsequent Event [Member] \| Jmj Financial [Member]
Subsequent Event [Line Items]
Convertible Debt																		$ 39,600	$ 67,515
Debt Instrument, Face Amount	$ 800,000
Net Proceeds Of Issuance Of Common Stock	50,000
Debt Instrument Purchase Price	$ 720,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Long-term Debt, Gross			525,000
Proceeds From Convertible Debt			100,000
Proceeds From Notes Payable			625,000
Remaining Available Principal Amount To Lend			95,000
Stock Issued During Period, Value, New Issues	$ 5,000,000
Debt Instrument Discount Percentage	10.00%
Debt Conversion Convertible Instrument Borrowed Amount	$ 500,000
Debt Conversion Convertible Instrument Remaining Borrowed Amount	$ 220,000
Debt Instrument, Maturity Date	Sep. 04, 2014
Debt Instrument, Convertible, Terms Of Conversion Feature	convertible promissory note is convertible at any time, in whole or in part, at JMJ Financials option into shares of the Companys common stock at the lesser of $2.65 or 70% of the average of the lowest two closing prices in the 20-day pricing period preceding a conversion.
Investors Minimum Beneficially Ownership Percentage	4.99%
Conversion of Stock, Shares Issued	2,000,000
Debt Instrument, Interest Rate Terms	18
Debt Instrument, Debt Default, Description of Notice of Default	150% of the outstanding principal amount of the note plus 100% of all interest, liquidated damages and other amounts owing under the note.
Subsequent Event [Member] \| Tonaquint Note [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Amount			$ 55,254
Stock Issued During Period, Shares, New Issues			33,309										11,466
Debt Instrument, Convertible, Conversion Price			$ 2.53								$ 3.00
Debt Instrument, Face Amount			$ 49,444
Interest Payable			$ 5,810
Debt Instrument Convertible Conversion Floor Price											$ 2.50
Convertible Notes Payable, Current											$ 108,000
Debt Instrument Purchase Price											$ 100,000
Debt Instrument, Interest Rate, Stated Percentage											20.00%
Repayments Of Debt											$ 2,000,000
Proceeds From Convertible Debt											$ 108,000
Stock Issued To Satisfy Second Installment Payment			21,843
Percentage Of Volume Weighted Average Price											80.00%
Subsequent Event [Member] \| Mr Moore [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage												12.00%
Stock Options Granted Under Incentive Plan												30,000
Annualized Compensation Monthly For Consulting Agreement												$ 350,000
Description Of Payment For Consulting Agreement												a one-time $100,000 payment if the Company closes a financing greater than $5,000,000 during the initial term of the agreement (which one-time payment may be increased to $429,076.59 at the Companys discretion if the financing exceeds $15,000,000)
Subsequent Event [Member] \| Yenson Co. Ltd. [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues										45,353
Issuance Of Warrants To Purchase Common Stock										22,161
Warrants Expiration Term										3 years
Stock Issued During Period, Value, New Issues										$ 100,000
Stock Issued During Period Price Per Share										$ 2.21
Percentage Of Warrant Coverage										50.00%
Issuance Of Warrants To Purchase Common Stock Exercise Price										$ 2.76
Subsequent Event [Member] \| Sale Of Stock Under Equity Enhancement Program [Member] \| Hanover Purchase Agreement [Member]
Subsequent Event [Line Items]
Stock Price		$ 2.81
Net Proceeds Of Issuance Of Common Stock		$ 29,516
Subsequent Event [Member] \| Sale Of Stock Under Equity Enhancement Program [Member] \| Tonaquint Note [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans		10,500
Subsequent Event [Member] \| May 2012 Note Financing [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Amount					$ 83,333										$ 83,333
Debt Instrument, Convertible, Conversion Price					$ 3.16								$ 3.16		$ 3.16		$ 3.16
Debt Conversion, Converted Instrument, Shares Issued					26,371
Subsequent Event [Member] \| Private Placement Agreement [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued for Services															4,000
Subsequent Event [Member] \| Private Placement [Member] \| Jmj Financial [Member]
Subsequent Event [Line Items]
Debt Instrument Origination Fee	$ 50,000
Convertible Notes Payable	$ 800,000
Debt Conversion, Converted Instrument, Shares Issued	19,231
Subsequent Event [Member] \| Minimum [Member]
Subsequent Event [Line Items]
Debt Instrument, Convertible, Conversion Price			$ 1.89
Subsequent Event [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Debt Instrument, Convertible, Conversion Price			$ 2.20